



SVIN 14<sup>TH</sup> ANNUAL MEETING  
**PROGRAM**

Phoenix, AZ ★ November 17-20 ★ Sheraton Grand at Wild Horse Pass



SOCIETY OF VASCULAR AND  
INTERVENTIONAL NEUROLOGY

# Welcome

## TO THE 2021 SVIN HYBRID ANNUAL MEETING



David Liebeskind, MD, FAAN,  
FAHA, FANA, FSVIN, FWSO



Ameer Hassan, DO,  
FAHA, FSVIN



Santiago Ortega-Gutierrez,  
MD, MSc, FSVIN, FAHA



Andrei Alexandrov, MD



Alexandra Czap, MD

On behalf of the Society of Vascular and Interventional Neurology (SVIN), I would like to welcome you all to the 14th Annual Meeting in Phoenix, Arizona, November 17 - 20, 2021! Although we have faced many challenges over the past year, our field has continued to innovate and grow, advancing our knowledge and ability to treat cerebrovascular diseases. Strokes don't take a break, and neither should we as a Society.

This year, we have created a unique hybrid program building from previous successful in-person meetings by incorporating novel virtual options to ensure that all national and international cerebrovascular practitioners from diverse disciplines have the opportunity to participate and share in the latest advancements in the field.

Our first day kicks off with a guided hiking tour for those brave early-risers and adventurers at heart. After, we will commence the annual meeting with the Stroke Center Workshop chaired by Drs. Andrei Alexandrov and Alexandra Czap. During our Annual MT2020+ Brunch, attendees will have the opportunity to learn about our global SVIN initiative, MT2020+, which aims to increase access to mechanical thrombectomy throughout the world and hear updates of the multiple achievements and collaborations spanning five continents. After brunch, we will hear from world experts on how to improve stroke systems of care and better fulfill requirements for stroke center certifications. In addition, workshops and debates will highlight the perspective of emergency medical services, clinicians using TNK for thrombolysis, and world experts on the latest treatments for ICH. Finally, our day would not be complete without hearing about the latest evidence on Mobile Stroke Units and its incorporation into our stroke systems of care.

Our second day will commence with debates on the hottest topics surrounding acute stroke intervention by world and society leaders. Let's hope for passionate debates and friendly fire from both sides! In the afternoon, we will enjoy our parallel track sessions on diagnostic challenges in vascular neurology and antiplatelet management in our APP session. We will have an engaging session on frontiers in endovascular stroke therapy featuring leaders in the field, and while it may come as no surprise, I was pleased to see that the lineup for this pivotal session is entirely female. Our last session will close with illuminating lectures on triage and controversial management of LVOs.

On Friday, we will be introduced to the latest advancements in hemorrhagic cerebrovascular disease and rehabilitation, and witness complex cases and bailouts presented by both our junior and senior members. This year, we have also included a new joint session with the Neurocritical Care Society where experts from both societies will share the latest research in vasospasm and reperfusion. We are thrilled to welcome Dr. Matthew J. Gounis, PhD, as our Keynote Speaker on Friday afternoon. Dr. Gounis is a biomedical engineer and tenured Professor of the Department of Radiology, University of Massachusetts Medical School. He co-founded the New England Center for Stroke Research at UMass in 2006 where the team works to bring new imaging and medical device technology from the bench to the patients.

New to the Annual meeting will be the SVIN Journal Launch Black and White Gala, held on Friday night at the Sheraton Grand at Wild Horse Pass. During this exciting event, we will celebrate together the launching our joint SVIN: AHA journal led by Dr. Ashutosh Jhadav, Editor-in-Chief. A formal dinner event with our SVIN and AHA associate editor team, followed by music on a beautiful night in the Phoenix desert, will provide a unique environment to catch up with friends old while celebrating this historic moment for our society.

Our final day, Saturday, will start with updates from ongoing clinical trials in the field, followed by the second joint Vascular and Interventional sessions, where all participants will be exposed to robust discussions and advancements in the latest topics on cerebrovascular disease. We will close the conference with a memorable half-day Fellows Course organized by SVIN Board members and industry sponsors.

The Abstract Committee, under the leadership of Alicia Castonguay, PhD, continues to meet the challenge of choosing the best scientific abstracts from more than 200 submissions. The Research Committee worked diligently to bring out the best of SVIN science to be highlighted in two platform presentation sessions. Additional meeting highlights will include networking opportunities during our welcome reception, our Women in Vascular and Interventional Neurology (WIN) Reception (with featured keynote speaker, Dr. Lisa Rotenstein, from Harvard Medical School), Members in Training Reception, and the Diversity Equity and Inclusion reception (with featured keynote speaker, Dr. Joseph Kass, from Baylor College of Medicine), where SVIN demonstrates the commitment to building a representative workforce within our field and to making the lifesaving treatments our specialties offer equally available to all members of society and to increase access to underrepresented vascular and interventional neurology physicians.

While the status of COVID-19 is always changing, SVIN is excited to host our first hybrid conference, and we will be taking all precautions to ensure the safety of our attendees and faculty while allowing an in-person presence this November. Due to the virus's capacity to transmit from person-to-person through respiratory droplets, the Center for Disease Control (CDC) has set recommendations, guidelines, and some prohibitions which SVIN adheres to comply. SVIN and its partners will be taking all appropriate precautions necessary, and the safety of the attendees, staff, and their families will always remain a top priority.

I would like to thank our entire Annual Meeting Committee and my Vice-Chair Dr. Sunil A. Sheth, Stroke Center Workshop Chairs, Nursing and Vascular Track Chairs, Abstract Committee, Fundraising Committee, SVIN's Executive Committee and Board of Directors, as well as everyone who has generously donated their time, effort, and patience to putting together the best possible agenda for this year's meeting. I would also like to recognize Dr. David Liebeskind for his outstanding term as president of our society. Dr. Liebeskind has enabled our society to grow and develop in ways that deserve the highest remarks. It is my honor to welcome Dr. Ameer Hassan as SVIN's new president for the 2022-2024 term, beginning at the 2021 Annual Meeting.

We wish to acknowledge and thank our gracious meeting exhibitors and sponsors for their continued participation in the SVIN Annual Meeting and the society. Please be sure to visit the exhibitor area and Top Supporter suites.

I thank the SVIN for the opportunity to lead this year's annual meeting and I look forward to an amazing time learning, networking, and building synergies with all of you in Phoenix!

Sincerely,

Santiago Ortega-Gutierrez, MD, MSc, FSVIN, FAHA  
Chair, 14th Annual SVIN Meeting

## WEDNESDAY, NOVEMBER 17<sup>TH</sup> (Stroke Center Day)

7:00 am – 9:00 am	Breakfast .....	Akime! Foyer
7:00 am – 8:30 am	Morning Recreational Activities .....	Akime! Foyer
7:00 am – 5:00 pm	Registration/Help Desk .....	Akime! Foyer
7:00 am – 5:00 pm	Speaker Ready Room .....	Rattlesnake
9:00 am – 11:00 am	MT2020+ Annual Update Brunch .....	Akime! 3 & 4
10:00 am – 5:00 pm	Tech Suites: Medtronic – <i>Roadrunner</i> , Penumbra – <i>Bird</i> , Stryker – <i>Jackrabbit</i> , Cerenovus – <i>Quail</i> , MicroVent – <i>Horse</i> .....	
10:45 am – 11:00 am	Coffee Break .....	Akime! Foyer
11:00 am – 11:10 am	Welcome to the Desert .....	Akime! 3 & 4
11:10 am – 12:00 pm	Developing Systems of Care .....	Akime! 3 & 4
12:00 pm – 12:55 pm	Lunch .....	Mesquite Terrace
12:00 pm – 6:15 pm	Exhibits Open .....	Akime! 1 & 2/Kave Ballroom
1:00 pm – 2:45 pm	New Developments: Pros and Cons .....	Akime! 3 & 4
2:45 pm – 3:15 pm	Exhibit Hall and E-Poster Viewing .....	Akime! 1 & 2/Kave Ballroom
3:15 pm – 4:00 pm	Treatment Options for Hemorrhagic Stroke .....	Akime! 3 & 4
4:00 pm – 5:15 pm	Happy Hour .....	Akime! 3 & 4
4:15 pm – 5:15 pm	A Battle of Wills: Mobile Stroke Units .....	Akime! 3 & 4
5:15 pm – 6:15 pm	Welcome Reception – <i>Sponsored by Penumbra</i> .....	Akime! 1 & 2/Kave Ballroom
6:30 pm – 9:00 pm	SVIN Board of Directors Meeting (Invite Only) .....	Deer/Scorpion
6:30 pm – 8:00 pm	CLOTS Workshop (Invite Only) – <i>Sponsored by Cerenovus</i> .....	Coyote/Buzzard/Eagle

## THURSDAY, NOVEMBER 18<sup>TH</sup>

7:00 am – 7:40 am	Breakfast Symposium with Rapid Medical .....	Coyote/Buzzard/Eagle
7:00 am – 5:30 pm	Registration / Help Desk .....	Akime! Foyer
7:00 am – 7:00 pm	Speaker Ready Room .....	Rattlesnake
8:15 am – 9:45 am	Welcome/Stroke Debates .....	Akime! 3 & 4
8:00 am – 4:00 pm	Tech Suites: Medtronic – <i>Roadrunner</i> , Penumbra – <i>Bird</i> , Stryker – <i>Jackrabbit</i> , Cerenovus – <i>Quail</i> , MicroVent – <i>Horse</i> , Imperative Care – <i>Thunder 1</i> .....	
9:45 am – 10:15 am	Business Meeting & Presidential Address .....	Akime! 3 & 4
10:15 am – 11:00 am	Coffee Break with Exhibitors & E-Poster Presentations .....	Akime! 1 & 2/Kave Ballroom
10:00 am – 4:00 pm	Exhibits Open .....	Akime! 1 & 2/Kave Ballroom
11:00 am – 12:00 pm	Platform Session I .....	Akime! 3 & 4
12:00 pm – 2:10 pm	Lunch with Exhibitors, E-Poster Viewing .....	Akime! 1 & 2/Kave Ballroom/Mesquite Terrace
12:00 pm – 2:10 pm	Lunch Symposia .....	Akime! 3 & 4
2:15 pm – 3:45 pm	APP Track .....	Deer/Scorpion
2:15 pm – 3:45 pm	NIR Track .....	Coyote, Buzzard, Eagle
2:15 pm – 3:45 pm	Vascular Neurology Track .....	Akime! 3 & 4
3:45 pm – 4:00 pm	Coffee Break with Exhibitors & E-Poster Presentations .....	Akime! 1 & 2/Kave Ballroom
4:00 pm – 5:30 pm	Endovascular + Vascular Neurology Joint Session 1 .....	Akime! 3 & 4
5:30 pm – 6:30 pm	Members in Training Reception (All Welcome) – <i>Sponsored by Cerenovus</i> .....	Coyote/Buzzard/Eagle
6:30 pm – 7:30 pm	Women in Vascular and Interventional Neurology (WIN) Reception – <i>Sponsored by Stryker</i> .....	Coyote/Buzzard/Eagle
6:30 pm – 7:30 pm	MT2020+ Industry Advisory Meeting .....	Deer/Scorpion

## FRIDAY, NOVEMBER 19<sup>TH</sup>

6:45 am – 8:00 am	14th Annual SVIN Top Supporter Breakfast (Invitation Only) .....	Gila Monster
7:00 am – 8:00 am	Breakfast with the Exhibitors .....	Akime! 1 & 2 / Kave Ballroom
7:00 am – 8:00 am	How To Get Published” Breakfast .....	Coyote/Buzzard
7:00 am – 5:30 pm	Registration / Help Desk .....	Akime! Foyer
7:00 am – 6:00 pm	Speaker Ready Room .....	Rattlesnake
8:00 am – 9:30 am	APP Track .....	Deer/Scorpion
8:00 am – 9:30 am	NIR Track .....	Coyote/Buzzard/Eagle
8:00 am – 9:30 am	Vascular Neurology Track .....	Akime! 3 & 4
8:00 am – 3:00 pm	Tech Suites: Medtronic – <i>Roadrunner</i> , Penumbra – <i>Bird</i> , Stryker – <i>Jackrabbit</i> , Cerenovus – <i>Quail</i> , MicroVent – <i>Horse</i> , Imperative Care – <i>Thunder 1</i> .....	
9:30 am – 10:15 am	Coffee Break with Exhibitors & E-Poster Presentations .....	Akime! 1 & 2/Kave Ballroom
9:30 am – 4:00 pm	Exhibits Open .....	Akime! 1 & 2/Kave Ballroom
10:15 am – 11:15 pm	Platform Session II .....	Akime! 3 & 4
11:15 am – 12:00 pm	Keynote Address .....	Akime! 3 & 4
12:00 pm – 2:35 pm	Lunch with Exhibitors, E-Poster Viewing .....	Akime! 1 & 2/Kave Ballroom/Mesquite Terrace
12:00 pm – 2:35 pm	Lunch Symposium .....	Akime! 3 & 4
2:35 pm – 3:30 pm	Aneurysms .....	Akime! 3 & 4
3:30 pm – 3:45 pm	Coffee Break with Exhibitors & E-Poster Presentations .....	Akime! 1 & 2/Kave Ballroom
3:45 pm – 4:35 pm	NCS Joint Session .....	Akime! 3 & 4
4:00 pm – 6:00 pm	GAPS Committee Meeting .....	Gila Monster
4:35 pm – 5:40 pm	Complex Cases and Bail-Out Techniques .....	Akime! 3 & 4
5:40 pm – 6:40 pm	DEI Reception – <i>Sponsored by Cerenovus</i> .....	Coyote/Buzzard/Eagle/Deer/Scorpion
7:00 pm – 10:00 pm	SVIN Black and White Gala (in celebration of S:VIN Journal Launch) – <i>Sponsored by Viz.ai</i> .....	Hemapi! Lawn

## SATURDAY, NOVEMBER 20<sup>TH</sup>

7:00 am – 8:00 am	Breakfast .....	Akime! 3 & 4
7:00 am – 12:00 pm	Registration / Help Desk .....	Akime! Foyer
7:00 am – 3:30 pm	Speaker Ready Room .....	Rattlesnake
8:00 am – 9:30 am	Clinical Trials Update - Stroke and Neurointerventional .....	Akime! 3 & 4
9:30 am – 10:45 am	Endovascular + Vascular Neurology Joint Session 2 .....	Akime! 3 & 4
10:45 am – 11:00 am	Coffee Break .....	Akime! Foyer
11:00 am – 12:00 pm	Fellows Course – Didactic .....	Akime! 3 & 4
12:00 pm – 12:30 pm	Fellows Course Lunch .....	Coyote/Buzzard/Eagle
12:30 pm – 3:30 pm	Fellows Course – Hands On .....	Kave Ballroom





# TABLE OF CONTENTS



General Information.....3

CME/CE Information.....5

Program.....6

Faculty .....16

Awards and Recognitions.....18

Exhibitor Listing .....19

About SVIN.....21



# GENERAL INFORMATION

## SVIN 14th Annual Meeting Program Description

The 2021 SVIN Hybrid Annual Meeting, taking place November 17th-20th virtually and at the Sheraton Grand at Wild Horse Pass in Phoenix, AZ, continues to be the premier academic venue with scientific presentations covering the full spectrum of cerebrovascular diseases. This year, recognized leaders in stroke and endovascular treatment will present cutting edge clinical and translational research in ischemic and hemorrhagic disease. Based on previous years' success, we will include three new parallel tracks and a fellows course to include more education for the entire "Stroke Team" including but not limited to nurses, advanced practice providers, coordinators, hospitalists, and vascular neurologists.

Our program will also include patients who have suffered from stroke, and their invaluable perspectives. Our initial stroke day will focus in the prehospital and hospital settings with regards to triage and treatment of ischemic and hemorrhagic diseases. The following two days we will continue finding out about the latest evidence and advancement on the treatment of large vessel occlusion (LVO) stroke in adults and pediatric population, intracranial and extracranial atherosclerosis, aneurysm, arteriovenous malformations and arteriovenous fistulas. Our program also includes a combined neurocritical care session in collaboration and partnership with leaders of the Neurocritical Care Society (NCS). We have incorporated additional sessions on translational research, robotics, and innovative use of endovascular therapies to refractory disease.

## Learning Objectives

Recognized leaders in stroke and endovascular treatment will present cutting edge clinical and translational research in ischemic and hemorrhagic disease. Based on previous years' success, we will include three new parallel tracks and a fellows course to include more education for the entire "Stroke Team" including but not limited to nurses, advanced practice providers, coordinators, hospitalists, and vascular neurologists.

**Target Audience:** Interventional Neurologists, Vascular Neurologists, Neurocritical Care Specialists, Neurologists, Neurohospitalists, Physician Affiliates, Clinical Pharmacists, Advanced Practice Providers, Nurses, Physician Assistants, Radiologists, Technicians, EMS/EMT Professionals, Fellows in Training, Residents, Medical Students, and other Allied Health Professionals.

## How to Claim CME for the SVIN 2021 Annual Meeting

**Claim your CME as easy as 1-2-3:**

1. Access the SVIN 2021 Annual Meeting Evaluation by using the following link:  
<https://cine-med.com/certificate.php?redirect=svin2021>
2. Complete the evaluation for sessions attended.
3. After you hit submit, an electronic copy will be emailed to you for your records.

Earn up to 21 AMA PRA Category 1 Credit(s)<sup>™</sup>

Please see page 5 for complete CME/CE information.


## Exhibit and Registration Desk Hours

### Registration/Help Desk Hours | Akimel Foyer

Wednesday, November 17 ..... 7:00 am – 5:00 pm MST  
Thursday, November 18 ..... 7:00 am – 5:30 pm MST  
Friday, November 19 ..... 7:00 am – 5:30 pm MST  
Saturday, November 20 ..... 7:00 am – 12:00 pm MST

### Exhibit Hall Hours | Akimel 1 & 2

Wednesday, November 17 ..... 12:00 pm – 6:15 pm MST  
Thursday, November 18 ..... 10:00 am – 4:00 pm MST  
Friday, November 19 ..... 9:30 am – 4:00 pm MST



# GENERAL INFORMATION

## WIFI INSTRUCTIONS

To access WiFi at the Sheraton Grand at Wild Horse Pass use WiFi network **Sheraton\_Conference** and **SVIN2021** as the passcode.



## VIRTUAL PLATFORM

Virtual Platform instructions with QR code **(USE THIS TO PARTICIPATE WITH THE AUDIENCE RESPONSE SYSTEM)**



## SHUTTLE BUS INFORMATION



There will be a shuttle bus provided to and from the Sheraton Hotel and the Wild Horse Pass Hotel and Casino for SVIN Annual Meeting attendee use only.

## ONSITE MAP



## ACCREDITATION OVERVIEW

SVIN 14th Annual Meeting  
November 17-20, 2021

### Target Audience

This activity is intended for all practitioners including Neurointerventionists, Interventional Neurologists, Interventional Neuroradiologists, Endovascular Neurosurgeons, Vascular Neurologists, Neurointensivists, Critical Care Physicians, Hospital Administrators, EMS leaders, ICU leaders, interventional lab leaders, nurses, physician assistants, and other related neurological or endovascular practitioners who care for a significant percent of their patients with cerebrovascular disease.

### Learning Objectives

At the conclusion of this activity, participants should be able to:

- Identify clinical pathways to improve accuracy of stroke diagnosis and time to treatment,
- Describe prehospital and emergency best-practice protocols and communication technologies to facilitate patient triage and treatment,
- Identify clinical pathways to improve accuracy of stroke diagnosis and time to treatment,
- Discuss the future of Interventional Neurology and national/international barriers to stroke treatment.

### Activity Goal

This activity is designed to address the following core and team competencies: *Patient Care, Medical Knowledge, System-Based Practice, Patient-Centered Care, Quality Improvement, and Work in Interdisciplinary Teams.*

### Non-Endorsement Statement

The provider verifies that sound education principles have been demonstrated in the development of this educational offering as evidenced by the review of its objectives, teaching plan, faculty, and activity evaluation process. The provider does not endorse or support the actual opinions or material content as presented by the speaker(s) and/or sponsoring organization.

### Disclosure

The provider adheres to accreditation requirements regarding industry support of continuing medical education. Disclosure of the planning committee and faculty's commercial relationships will be made known at the activity. Speakers are required to openly disclose any limitations of data and/or any discussion of any off-label, experimental, or investigational uses of drugs or devices in their presentations.

### Disclosure Summary

See separate handout.



### Accreditation

In support of improving patient care, this activity has been planned and implemented by Cine-Med and the Society of Vascular and Interventional Neurology. Cine-Med is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Cine-Med designates this live activity for a maximum of 21 *AMA PRA Category 1 Credit(s)*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity provides 21 contact hours for nurses.

All other healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of Certificates of Participation for activities designated for *AMA PRA Category 1 Credits*<sup>™</sup>, consult your professional licensing board.

**Certificates: To claim your CME/CE credits, complete the online Credit and Evaluation form using the following URL:**  
<https://cine-med.com/certificate.php?redirect=svin2021>

This is a one-time credit submission. Credits for all days should be tracked at the completion of the meeting. Participants will be able to download or print a certificate once the form has been submitted.

### Commercial Support

See separate handout of list of activity supporters.

### Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

### Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The Society of Vascular and Interventional Neurology (SVIN) and Cine-Med specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

### Disclosure Declaration

It is the policy of The Society of Vascular and Interventional Neurology (SVIN) and Cine-Med to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by The Society of Vascular and Interventional Neurology (SVIN) and Cine-Med., Advancing Knowledge in Healthcare prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content, notification of independent and certified CME/CE expectations, referral to National Faculty Initiative training, restriction of topic area or content, restriction to discussion of science only, amendment of content to eliminate discussion of device or technique, use of other faculty for discussion of recommendations, independent review against criteria ensuring evidence support recommendation, moderator review, and peer review. Cine-Med planners and reviewers have no relevant financial relationships to disclose.



# PROGRAM

## ANNUAL MEETING PROGRAM OVERVIEW

Despite the challenging times we are all facing, The Society of Vascular and Interventional Neurology (SVIN) continues with its mission to represent the advancement of interventional neurology as a field with the ultimate goal of improving clinical care and outcomes of patients with stroke and cerebrovascular disease.

The 2021 SVIN Hybrid Annual Meeting, taking place November 17th-20th virtually and at the Sheraton Grand at Wild Horse Pass in Phoenix, AZ, continues to be the premier academic venue with scientific presentations covering the full spectrum of cerebrovascular diseases. This year, recognized leaders in stroke and endovascular treatment will present cutting edge clinical and translational research in ischemic and hemorrhagic disease. Based on previous years' success, we will include three new parallel tracks and a fellows course to include more education for the entire "Stroke Team" including but not limited to nurses, advanced practice providers, coordinators, hospitalists, and vascular neurologists.

For the first time ever, we will also be including patients who have suffered from stroke, and their invaluable perspectives, in our meeting. Our initial stroke day will focus in the prehospital and hospital settings with regards to triage and treatment of ischemic and hemorrhagic diseases. The following two days we will continue finding about the latest evidence and advancement on the treatment of large vessel occlusion (LVO) stroke in adults and pediatric population, intracranial and extracranial atherosclerosis, aneurysm, arteriovenous malformations and arteriovenous fistulas. Our program also includes a combined neurocritical care session in collaboration and partnership with leaders of the Neurocritical Care Society (NCS). We have incorporated additional sessions on translational research, robotics, and innovative use of endovascular therapies to refractory disease. Those who attend and participate in SVIN's Annual Meeting will gain access to not only the key opinion leaders in the field, but an opportunity to promote your society's central role in this space.

## Wednesday, November 17 – Stroke Center Day

7:00 am – 9:00 am	Breakfast.....Akimel Foyer
7:00 am – 8:30 am	<b>Raising Arizona: Guided/Talk Hiking Tour (Registration Required).....Akimel Foyer</b> <i>Group Leaders:</i> Ashutosh Jadhav, MD, PhD, FSVIN Mohammad Teleb, MD Andrei Alexandrov, MD
7:00 am – 5:00 pm	Registration/Help Desk.....Akimel Foyer
7:00 am – 5:00 pm	Speaker Ready Room..... Rattlesnake
9:00 am – 11:00 am	<b>MT2020+ Annual Update Brunch.....Akimel 3 &amp; 4</b>
9:00 am – 9:15 am	Welcome to MT2020+: Mission & Overview – <i>Dileep Yavagal, MD, MBBS, FSVIN, FAAN, FAHA</i>
9:15 am – 9:30 am	Development and Progress of the MT2020+ Regional Committees – <i>Violiza Inoa, MD</i>
9:30 am – 9:40 am	Social & Cultural Barriers to Stroke Care in LMIC – <i>Fawaz Al-Mufti, MD</i>
9:40 am – 9:50 am	Angels and MT2020+ Pilot Program Collaborations – <i>Thomas Fischer</i>
9:50 am – 10:10 am	Building Telestroke Networks in Low- and Middle-Income Countries – <i>Eloy Mansilla, MD and Andrew Southerland, MD, MSc</i>
10:10 am – 10:15 am	Q&A – <i>Violiza Inoa, MD and Nabeel Herial, MD</i>
10:15 am – 10:40 am	Panel: Stroke Thrombectomy Education and Training in the Underserved Areas Moderator: <i>Nabeel Herial, MD</i> Moderator: <i>Santiago Ortega-Gutierrez, MD, MSc, FSVIN</i> Panelists: <i>Vikram Huded, MD, DM, Nelson Maldonado, MD, Zongrong Miao, MD, Atilla Özcan Özdemir, MD, Boris Pabon, MD, and Victor Urrutia, MD, FAHA</i>
10:40 am – 10:50 am	Stroke Center Mapping and App Update – <i>Nabeel Herial, MD and Kaiz Asif, MD, FSVIN</i>
10:50 am – 11:00 am	Q&A and Final Remarks – <i>Violiza Inoa, MD and Nabeel Herial, MD</i>


<b>10:00 am – 5:00 pm</b>	<b>Tech Suites</b> Medtronic – <i>Roadrunner</i> Penumbra – <i>Bird</i> Stryker – <i>Jackrabbit</i> Cerenovus – <i>Quail</i> MicroVention – <i>Horse</i>
<b>10:45 am – 11:00 am</b>	<b>Coffee Break.....Akimel Foyer</b>
<b>11:00 am – 11:10 am</b>	<b>Welcome to the Desert – Andrei Alexandrov, MD &amp; Alexandra Czap, MD ..... Akimel 3 &amp; 4</b>
<b>11:10 am – 12:00 pm</b>	<b>“Yes, But It’s a Dry Heat!” Developing Systems of Care and Surviving Certifications..... Akimel 3 &amp; 4</b> Moderator: Thomas Devlin, MD, PhD, FSVIN Moderator: Aaron Grossman, MD, PhD
11:10 am – 11:20 am	Hub and Spokes Stroke Patient Chain of Survival During the Pandemic – Kara Sands, MD
11:20 am – 11:30 am	Comprehensive Stroke Centers: Time for a Paradigm Shift – Jeffrey Saver, MD, FAHA, FAAN, FANA
11:30 am – 11:40 am	Building Successful Networks in the Developing World – Violiza Inoa, MD
11:40 am – 11:50 am	Lessons from Successful TJC and DNV Accreditations – Alisia Hindman, DNP, AGACNP, SCRNP
11:50 am – 12:00 pm	Q&A
<b>12:00 pm – 6:15 pm</b>	<b>Exhibit Hall Open .....Akimel 1 &amp; 2/Kave Ballroom</b>
<b>12:00 pm – 12:55 pm</b>	<b>Lunch, E-Poster Viewing &amp; Exhibit Hall ..... Akimel 1 &amp; 2/Kave Ballroom/Mesquite Terrace</b>
<b>1:00 pm – 2:45 pm</b>	<b>Wyatt Earp: “You Gonna Do Somethin? Or Are You Just Gonna Stand There and Bleed?” New Developments and Pros and Cons ..... Akimel 3 &amp; 4</b> Moderator: Robin Novakovic-White, MD, FSVIN, FAHA, FAAN Moderator: Kaiz Asif, MD, FSVIN
	<b>EMS Roundtable on Stroke Systems of Care in the US</b>
1:00 pm – 1:05 pm	Midwest – Nicholas M. Mohr, MD, MS
1:05 pm – 1:10 pm	Dallas-Fort Worth – Paul E. Pepe, MD, MPH, FAEMS, MCCM, MACP
1:10 pm – 1:15 pm	Dallas-Fort Worth – Donald Tucker, LP
	<b>Switching Systems to TNK</b>
1:20 pm – 1:30 pm	Initial US Experience – Steve Warach, MD, PhD
1:30 pm – 1:40 pm	Australian Experience – Skye Coote, MSN
	<b>Man Versus Machines</b>
1:40 pm – 1:50 pm	Devices on the Horizon – Wade Smith, MD, PhD
1:50 pm – 2:00 pm	Clinical Exam is Still the Gold Standard – Tudor Jovin, MD, FSVIN
2:00 pm – 2:10 pm	Modalities to Access the Stroke “Core” – David Liebeskind, MD, FAAN, FAHA, FANA, FSVIN, FWSO
2:10 pm – 2:20 pm	Automated Softwares – Sunil Sheth, MD
2:20 pm – 2:45 pm	Q&A
<b>2:45 pm – 3:15 pm</b>	<b>Exhibit Hall and E-Poster Viewing..... Akimel 1 &amp; 2/Kave Ballroom</b>

# PROGRAM

3:15 pm – 4:00 pm	<b>Doc Holliday: “I Have Two Guns, One For Each of Ya.”</b> <b>Treatment Options for Hemorrhagic Strokes</b> ..... Akimel 3 & 4 <i>Moderator: Mohamed Teleb, MD</i> <i>Moderator: Afshin Divani, PhD, FAHA</i>
3:15 pm – 3:25 pm	Modern Medicine: Management of ICH – <i>Nicole Gonzales, MD</i>
3:25 pm – 3:35 pm	Minimally Invasive: Surgical Treatment of ICH – <i>Christopher Kellner, MD</i>
3:35 pm – 3:45 pm	TNKase Associated Hemorrhage: Real World Experience – <i>Lee Birnbaum, MD, MS</i>
3:45 pm – 4:00 pm	Q&A
4:00 pm – 5:15 pm	<b>Happy Hour</b> ..... Akimel 3 & 4
4:15 pm – 5:15 pm	<b>“3:10 to Yuma.” A Battle of Wills: Mobile Stroke Units</b> ..... Akimel 3 & 4 <i>Joint Session for Stroke Day and Main Conference Registrants</i> <i>Moderator: May Nour, MD</i> <i>Moderator: Andrei Alexandrov, MD</i>
4:15 pm – 4:25 pm	Systemic tPA Remains the First-line Treatment for Ischemic Stroke – <i>Alexandra Czap, MD</i>
4:25 pm – 4:35 pm	A Brief History and Current State of MSUs – <i>Anne Alexandrov, MD, PhD, RN, AGACNP-BC, CCRN, NVRN-BC, ANVP-BC, FAAN</i>
4:35 pm – 4:55 pm	Keynote Lecture: The BEST-MSU Trial and Implications for Regional Systems of Care – <i>James Grotta, MD</i>
4:55 pm – 5:15 pm	Panel Discussion: Is the MSU a “Marketing Ploy”? – <i>Tudor Jovin, MD, FSVIN, Mohammad Jumaa, MD, FSVIN, Osama Zaidat, MD, FSVIN, Skye Coote, NP, CCRN, MN, NVRN-BC, ANVP-BC</i>
5:15 pm – 6:15 pm	<b>Welcome Reception with Exhibitors –</b> <b>Sponsored by Penumbra</b> ..... Akimel 1 & 2/Kave Ballroom
6:15 pm – 9:00 pm	<b>SVIN Board of Directors Meeting</b> ( <i>invite only</i> ) ..... Scorpion/Deer
6:30 pm – 8:00 pm	<b>CLOTS Workshop – Sponsored by Cerenovus</b> ..... Coyote/Buzzard/Eagle

## Thursday, November 18

7:00 am – 7:40 am	<b>Breakfast Symposium with Rapid Medical (Non-CME)</b> ..... Coyote/Buzzard/Eagle <b>Emerging technologies in Ischemic Stroke</b> <i>Panelists: Ameer Hassan, DO, FAHA, FSVIN, Guy Raphaeli, MD</i>
7:00 am – 5:30 pm	<b>Registration/Help Desk</b> ..... Akimel Foyer
7:00 am – 7:00 pm	<b>Speaker Ready Room</b> ..... Rattlesnake
8:00 am – 8:15 am	<b>Welcome to the 14th SVIN Annual Meeting –</b> <i>Santiago Ortega-Gutierrez, MD, MSc, FAHA, FSVIN</i> ..... Akimel 3 & 4
8:00 am – 4:00 pm	<b>Tech Suites</b> Medtronic – <i>Roadrunner</i> Penumbra – <i>Bird</i> Stryker – <i>Jackrabbit</i> Cerenovus – <i>Quail</i> MicroVention – <i>Horse</i> Imperative Care – <i>Thunder 1</i>
8:15 am – 9:30 am	<b>Debates</b> ..... Akimel 3 & 4 <i>Moderator: Thanh Nguyen, MD, FRCPc, FSVIN, FAHA</i> <i>Moderator: James Siegler, MD</i>





8:15 am – 8:25 am	<b>Debate #1: Best approach for M2 and beyond: Endovascular vs. Medical</b>
8:25 am – 8:35 am	Medical management – <i>Andrew Demchuk, MD, FRCPC</i> Endovascular treatment – <i>Raul Nogueira, MD, FSVIN</i>
8:35 am – 8:45 am	<b>Debate #2: Is It Time to Skip tPA Before Endovascular Therapy?</b>
8:45 am – 8:55 am	It Is Time – <i>Jeffrey Saver, MD, FAHA, FAAN, FANA</i> It is Not Time – <i>Georgios Tsivgoulis, MD, PhD, MSc, FESO, FEAN, FAAN</i>
8:55 am – 9:05 am	<b>Debate #3: When Should Endovascular Therapy be Offered?</b>
9:05 am – 9:15 am	Stick to the Guidelines – <i>Jenny Tsai, MDCM, FRCPC</i>
9:15 am - 9:25 am	Pushing the Guidelines – <i>Michael Chen, MD</i> Q&A
9:25 am - 9:45 am	<b>Debate #4: AURORA Debate</b> AURORA Investigators
<b>9:45 am - 10:15 am</b>	<b>Business Meeting &amp; Presidential Address ..... Akimel 3 &amp; 4</b> <i>David Liebeskind MD, FAAN, FAHA, FANA, FSVIN, FWSO</i>
<b>10:15 am - 11:00 am</b>	<b>Coffee Break with E-Poster Viewing &amp; Exhibitors ..... Akimel 1 &amp; 2/Kave Ballroom</b>
<b>10:00 am – 4:00 pm</b>	<b>Exhibits Open..... Akimel 1 &amp; 2/Kave Ballroom</b>
<b>11:00 am – 12:00 pm</b>	<b>Platform Sessions..... Akimel 3 &amp; 4</b> <i>Moderator: Mudassir Farooqui, MD, MPH</i> <i>Moderator: Shuichi Suzuki, MD, PhD</i>
11:00 am – 11:08 am	Vertebral Artery Origin Treatment by Endovascular Techniques Registry (VOTER): Safety in the First 20 Cases Entity – <i>Randall Edgell, MD, FSVIN</i>
11:08 am – 11:16 am	Safety and Efficacy of Surpass Streamline for Intracranial Aneurysms: A Multicenter US Real-World Experience (SESSIA) – <i>Juan Vivanco-Suarez, MD</i>
11:16 am – 11:24 am	Incidence and predictors of delayed functional independence in the TREVO retriever registry – <i>Shashvat Desai, MD</i>
11:24 am – 11:32 am	ANA Catheter System, Combined With a Stent Retriever in Acute Ischemic Stroke Trial (SOLONDA) – <i>Marc Ribo, MD</i>
11:32 am – 11:40 am	Hospital Cost of DTAS Compared to ED Transfers for LVOs Undergoing Mechanical Thrombectomy – <i>Joshua S. Catapano, MD</i>
11:40 am – 11:48 am	Mobile Stroke Unit Process Metrics in Large Vessel Occlusion Stroke Patients: BEST-MSU Substudy – <i>Alexandra Czap, MD</i>
11:48 am – 11:56 am	Integrated Geomapping Tool of Certified Stroke Centers in United States: A SVIN MT2020+ Committee Collaboration – <i>Evan Kolesnick, MS</i>
11:56 am – 12:00 pm	Q&A
<b>12:00 pm – 2:10 pm</b>	<b>Lunch, E-Poster Viewing &amp; Exhibit Hall..... Akimel 1 &amp; 2/Kave Ballroom/ Mesquite Terrace</b>
<b>12:00 pm – 12:40 pm</b>	<b>Industry Lunch Symposium with Medtronic (Non-CME)..... Akimel 3 &amp; 4</b> <b>New Frontiers in Neurointervention: Shielded by Science</b> <i>Panelists: Matthew Gounis, PhD, University of Massachusetts,</i> <i>Santiago Ortega-Gutierrez, MD, University of Iowa, David Fiorella, MD,</i> <i>Stony Brook University, Ajit Puri, MD, UMass Memorial Health</i>
<b>12:45 pm – 1:25 pm</b>	<b>Industry Lunch Symposium with Penumbra (Non-CME) ..... Akimel 3 &amp; 4</b> <b>Adapting To The Case: LVO to Distal in the Real World</b> <i>Panelists: Mohamed Teleb, MD, Banner Desert Medical, Ashish Nanda, MD,</i> <i>SSM Healthy Medical Group</i>

# PROGRAM

**1:30 pm – 2:10 pm**      **Industry Lunch Symposium with Stryker (Non-CME) ..... Akimel 3 & 4**  
**The Push, the Fluff, and the Ugly: Improving Clot**  
**Attachment with Trevo NXT ProVue Retriever**  
*Facilitated by: Raul Nogueira, MD*  
*Presented by: Diogo Haussen, MD, FSVIN, Michael G. Abraham, MD, FAHA, FSVIN, Nima Aghaebrahim, MD*

**2:15 pm – 3:45 pm**      **APP: Antiplatelets: What to Select, How to Prescribe, and Why ..... Deer/Scorpion**  
Moderator: *Anne Alexandrov, MD, PhD, RN, AGACNP-BC, CCRN, NVRN-BC, ANVP-BC, FAAN*  
Moderator: *Julie Shawver, PA-C*

2:15 pm – 2:40 pm      Pharmacology of Antiplatelet Agents – *Samarth Shah, PharmD, BCPS*  
2:40 pm – 3:05 pm      Antiplatelet Secondary Prevention Evidence – *Alicia Richardson, MSN, RN, ACCNS-AG*  
3:05 pm – 3:40 pm      Debate - From P2Y12 to Antiplatelet Selection: How Best to Manage Specific Cases – *Pankajavalli Ramakrishnan, MD, PhD, David Liebeskind, MD, FAAN, FAHA, FANA, FSVIN, FWSO, and Mouhammad Jumaa, MD, FSVIN*  
3:40 pm – 3:45 pm      Q&A

**2:15 pm – 3:45 pm**      **Expansion of EVT: Novel Therapeutic Approaches..... Coyote/Buzzard/Eagle**  
Moderator: *Violiza Inoa, MD*  
Moderator: *Sandra Narayanan, MD, FAHA, FANA, FSVIN*

2:15 pm – 2:25 pm      Intra-Arterial Chemotherapy for Pediatric Retinoblastoma – *Stavropoula Tjoumakaris, MD, FAANS, FAHA*  
2:25 pm – 2:35 pm      Acute Stroke Assessment and Neuroendovascular Care in the Cardiac Cath Lab – *Dorothea Altschul, MD, FSVIN*  
2:35 pm – 2:45 pm      Endovascular Approaches to Venous Sinus Thrombosis – *Cynthia Kenmuir, MD, PhD, FSVIN*  
2:45 pm – 2:55 pm      Novel Endovascular Treatment Strategies for Cerebral Vasospasm – *Robin Novakovic-White, MD, FSVIN, FAHA, FAAN*  
2:55 pm – 3:05 pm      Mechanical Properties and Flow Characteristics of Vascular Malformations – *Nina Moore, MD*  
3:05 pm – 3:15 pm      EVT Expansion: Research Perspective – *Alicia Castonguay, PhD, FAHA, FSVIN*  
3:15 pm – 3:25 pm      An Endovascular Approach to AVM Treatment for Cure – *Johanna Fifi, MD, FSVIN*  
3:25 pm – 3:45 pm      Q&A

**2:15 pm – 3:45 pm**      **Vascular Neurology: Diagnostic and Therapeutic Challenges: Everything But the Bread and Butter..... Akimel 3 & 4**  
Moderator: *Elissa Ortolani, MD*  
Moderator: *Esteban Cheng-Ching, MD*

2:15 pm – 2:25 pm      Carotid Web: Management of an Under-recognized Entity – *Diogo Haussen, MD, FSVIN*  
2:25 pm – 2:35 pm      Moya-Moya Disease: When is the Right Time to Revascularize? – *Michael Lawton, MD*  
2:35 pm – 2:45 pm      Idiopathic Intracranial Hypertension and Venous Stenting – *Felipe Albuquerque, MD*  
2:45 pm – 2:55 pm      Applications of Robotics in Endovascular Surgery – *Vitor Mendes Pereira, MD, MSc*  
2:55 pm – 3:05 pm      Central Retinal Artery Occlusion: Time is Vision – *Oana Dumitrascu, MD, MSc, FANOS*  
3:05 pm – 3:15 pm      Stem Cells for Stroke – *Dileep Yavagal, MD, MBBS, FSVIN, FAAN, FAHA*  
3:15 pm – 3:25 pm      Pediatric Stroke: Improving Patient Selection for Endovascular Therapy – *Todd Abruzzo, MD, FAHA*  
3:25 pm – 3:45 pm      Q&A

**3:45 pm – 4:00 pm**      **Coffee Break with Exhibitors & E-Poster Viewing ..... Akimel 1 & 2/Kave Ballroom**



<b>4:00 pm – 5:30 pm</b>	<b>Endovascular + Vascular Neurology Joint Session 1 ..... Akimel 3 &amp; 4</b> <i>Moderator: Amrou Sarraj, MD</i> <i>Moderator: Alicia Zha, MD</i>
4:00 pm – 4:10 pm	EMS Structure- How to Get Involved in Your Regional Pre-Hospital System of the Care? – <i>Mouhammad Jumaa, MD, FSVIN</i>
4:10 pm – 4:20 pm	Optimizing Pre-Hospital Stroke Triage, Bringing Stakeholders to the Table – <i>Natalia Perez de la Ossa, PhD</i>
4:20 pm – 4:30 pm	The 2 A.M. Stroke Triage Debate, Who Calls the Shots on LVO?
4:30 pm – 4:40 pm	Neuro-Interventionalist's View – <i>Kaiz Asif, MD, FSVIN</i>
4:40 pm – 4:50 pm	The 2 A.M. Stroke Triage Debate, Who Calls the Shots on LVO? Vascular Neurology View – <i>Alexandra Czap, MD</i>
4:50 pm – 5:00 pm	Best approach to tandem occlusion: acute stenting versus not – <i>Santiago Ortega-Gutierrez, MD, MSc, FSVIN</i>
5:00 pm – 5:10 pm	Is Perfect the Enemy of Good? Intra-Arterial Thrombolysis After Mechanical Thrombectomy – <i>Syed Zaidi, MD, FSVIN</i>
5:10 pm – 5:30 pm	The Sweet Spot, Blood Pressure Management after Successful Mechanical Thrombectomy – <i>Eva Mistry, MBBS, MSCI</i> Q&A
<b>5:30 pm – 6:30 pm</b>	<b>Members in Training (MIT) Reception –</b> <b>Sponsored by Cerenovus .....Coyote/Buzzard/Eagle</b>
<b>6:30 pm – 7:30 pm</b>	<b>Women in Vascular and Interventional Neurology</b> <b>(WIN) Reception – Sponsored by Stryker..... Coyote/Buzzard/Eagle</b>
<b>6:30 pm – 7:30 pm</b>	<b>MT2020+ Industry Advisory Meeting.....Deer/Scorpion</b>

## Friday, November 19

<b>6:45 am – 8:00 am</b>	<b>14th Annual SVIN Top Supporter Breakfast (Invitation Only).....Gila Monster</b>
<b>7:00 am – 8:00 am</b>	<b>Breakfast with the Exhibitors .....Akimel 1 &amp; 2/Kave Ballroom</b>
<b>7:00 am – 8:00 am</b>	<b>“How To Get Published” Breakfast –</b> <i>Maxim Mokin, MD, Jeffrey Saver, MD, FAHA, FAAN, FANA, and</i> <i>Ashutosh Jadhav, MD, PhD, FAHA, FSVIN ..... Coyote/Buzzard</i>
<b>7:00 am – 5:30 pm</b>	<b>Registration &amp; Help Desk Open.....Akimel Foyer</b>
<b>7:00am – 6:00 pm</b>	<b>Speaker Ready Room..... Rattlesnake</b>



# PROGRAM

**8:00 am – 9:30 am** **APP: On-Boarding New Acute Stroke Advance Practice Providers .....Deer/Scorpion**  
*Moderator: Anne Alexandrov, MD, PhD, AGANCP-BC, CCRN, NVRN-BC, ANVP-BC, FAAN*  
*Moderator: Skye Coote, NP, CCRN, MN, ANVP-BC, NVRN-BC*

8:00 am – 8:25 am Developing an Incentive-Based Comprehensive Orientation Program –  
*Jennifer Patterson, MSN, ACNP-BC, CCRN, FHM*

8:25 am – 8:50 am Building APP Expertise in Neuroimaging and Neurointerventional Lab Roles –  
*Abbigayle Doerr, DNP, APRN, FNP-BC, ANVP-BC*

8:50 am – 9:15 am Maximizing APP Team Contributions – *Julie Shawver, PA-C*

9:15 am – 9:30 am Q&A

**8:00 am – 9:30 am** **Technical Approaches to Neurovascular Disease .....Coyote/Buzzard/Eagle**  
*Moderator: May Nour, MD*  
*Moderator: Conrad Liang, MD, PhD*

8:00 am – 8:10 am Robotic Endovascular Navigation and Future for NeuroInterventional Care –  
*Satoshi Tateshima, MD*

8:10 am – 8:30 am Management of Slow Flow Vascular Malformations – *Mesha Martinez, MD*

8:30 am – 8:40 am Technical Approaches to CCF Treatment – *Viktor Szeder, MD, PhD, MSc, FSVIN*

8:40 am – 8:50 am Middle Meningeal Artery Embolization – *Max Mokin, MD*

8:50 am – 9:00 am Arterial Intracranial Stenting – *Ameer Hassan, DO, FAHA, FSVIN*

9:00 am – 9:10 am Endovascular Treatment of Spinal Dural Arteriovenous fistulas – *Andrew Ducruet, MD*

9:10 am – 9:30 am Q&A

**8:00 am – 9:30 am** **Vascular Neurology: There is Life After Stroke: Expanding Our Understanding of Stroke Recovery and Outcomes.....Akimel 3 & 4**  
*Moderator: Waldo Guerrero, MD*  
*Moderator: Sujan Reddy, MD, MPH*

8:00 am – 8:10 am Dissections and Recovery – *Amir Shaban, MD*

8:10 am – 8:20 am COVID-19 Impact on Stroke Recovery and Rehab: Impact of COVID-19 in Acute Stroke Care – *James Siegler, MD*

8:20 am – 8:30 am Sex Differences in Stroke Recovery – *Louise McCullough, MD, PhD*

8:30 am – 8:40 am VR for Neuro Recovery – *Tudor Jovin, MD, FSVIN*

8:40 am – 8:50 am Cerebral Amyloid Angiopathy Related Hemorrhage – *Nandakumar Nagaraja, MD, MS, FAHA*

8:50 am – 9:00 am mHealth for Secondary Prevention and Recovery – *Marc Ribó, MD*

9:00 am – 9:10 am New Paradigms in Secondary Prevention – *Jussie Lima, MD*

9:10 am – 9:30 am Q&A

**8:00 am – 3:00 pm** **Tech Suites**  
 Medtronic – *Roadrunner*  
 Penumbra – *Bird*  
 Stryker – *Jackrabbit*  
 Cerenovus – *Quail*  
 MicroVention – *Horse*  
 Imperative Care – *Thunder 1*

**9:30 am – 10:15 am** **Coffee Break with Exhibitors & E-Poster Viewing .....Akimel 1 & 2/Kave Ballroom**

**9:30 am – 4:00 pm** **Exhibits Open.....Akimel 1 & 2/Kave Ballroom**

**10:15 am – 11:15 am** **Platform Session 2.....Akimel 3 & 4**  
*Moderator: Kaustubh Limaye, MD*  
*Moderator: Osama Zaidat, MD, FSVIN*

10:15 am – 10:23 am Analysis of Protein Network to Predict Cognition Among Emergent Large Vessel Occlusion Undergoing Mechanical Thrombectomy– *Chintan Rupareliya, MD*

10:23 am – 10:31 am	Endovascular Treatment for Spetzler-Martin Grade III Pediatric Arteriovenous Malformations – <i>Aaron Rodriguez-Calienes, MD</i>
10:31 am – 10:39 am	Direct to Angiography Suite versus Conventional Imaging in Suspected Large Vessel Occlusion Strokes: A Meta-Analysis – <i>Mahmoud H. Mohammaden, MD, MSc</i>
10:39 am – 10:47 am	Influence of Catheter Tip Position and Aspiration Technique on ADAPT Revascularization Success with Various Catheters – <i>Raul Nogueira, MD, FSVIN</i>
10:47 am – 10:55 am	Local Stroke Center Characteristics to Optimize Pre-Hospital Triage in Acute Stroke: Secondary Analysis of RACECAT – <i>Marta Olive-Gadea, MD</i>
10:55 am – 11:03 am	Management of Acute Ischemic Stroke Patients with Tandem Lesions – <i>Mudassir Farooqui, MD, MPH</i>
11:03 am – 11:11 am	Non-Contrast CT versus CTP or MRI Selection in Late Presentation of Large Vessel Occlusion Stroke – <i>Thanh Nguyen, MD, FSVIN</i>
11:11 am – 11:15 pm	Q&A
<b>11:15 am – 12:00 pm</b>	<b>Keynote Address ..... Akimel 3 &amp; 4</b> <i>Introduction: Santiago Ortega-Gutierrez, MD, MSc, FSVIN</i> <i>Speaker: Matthew J. Gounis, PhD</i>
<b>12:00 pm – 2:35 pm</b>	<b>Lunch, E-Poster Viewing &amp; Exhibit Hall..... Akimel 1 &amp; 2/Kave Ballroom/ Mesquite Terrace</b>
<b>12:00 pm – 12:35 pm</b>	<b>Industry Lunch Symposium with MicroVention (Non-CME) ..... Akimel 3 &amp; 4</b> <b>Early Clinical Experience with BOBBY. A New Generation Balloon Guide Catheter</b> <i>Panelist: Bharathi D. Jagadeesan, MD</i>  <b>Flow Redirection Endoluminal Device (FRED) for Treatment of Intracranial Aneurysms: A Systematic Review</b> <i>Panelist: Jason M. Davies, MD, PhD</i>
<b>12:40 pm – 1:15 pm</b>	<b>Industry Lunch Symposium with Cerenovus (Non-CME) ..... Akimel 3 &amp; 4</b> <b>Bringing Precision Medicine to Endovascular Stroke Treatment</b> <i>Panelist: Raul Nogueira, MD</i>
<b>1:20 pm – 1:55 pm</b>	<b>Industry Lunch Symposium with Imperative Care (Non-CME)..... Akimel 3 &amp; 4</b> <b>Speed Matters: How the Zoom Stroke Solution™ Accelerates Innovation from all Angles</b> <i>Panelist: Dr. Sunil Sheth</i>
<b>2:00 pm – 2:35 pm</b>	<b>Industry Lunch Symposium with Viz.ai (Non-CME)..... Akimel 3 &amp; 4</b> <b>Impact on AI on Vascular Interventional Neurology</b> <i>Panelist: Ameer Hassan, DO, FAHA, FSVIN</i>



# PROGRAM

<b>2:35 pm – 3:30 pm</b>	<b>Aneurysms .....</b> <b>Akimel 3 &amp; 4</b> <i>Moderator: Gabor Toth, MD, FAHA</i> <i>Moderator: Sudeepta Dandapat, MD</i>
2:35 pm – 2:45 pm	Emerging Endovascular Strategies for Wide-neck Aneurysms – <i>Lucas Eljovich, MD, FSVIN</i>
2:45 pm – 2:55 pm	Novel Devices for the Treatment of Aneurysms – <i>Mario Martinez-Galdamez, MD</i>
2:55 pm – 3:05 pm	Flow diverters for the treatment of ruptured aneurysms – <i>Italo Linfante, MD, FAHA</i>
3:05 pm – 3:15 pm	Can We Predict Aneurysm Rupture Based on Morphological Data? – <i>Edgar Samaniego, MD, MS, FAAN, FSVIN</i>
3:15 pm – 3:25 pm	Oral Flora as Etiology of Aneurysm Rupture? – <i>Juhana Frosen, MD, PhD</i>
3:25 pm – 3:30 pm	Q&A
<b>3:30 pm – 3:45 pm</b>	<b>Coffee Break with Exhibitors &amp; E-Posters.....</b> <b>Akimel 1 &amp; 2/Kave Ballroom</b>
<b>3:45 pm – 4:35 pm</b>	<b>NCS Joint Session .....</b> <b>Akimel 3 &amp; 4</b> <i>Moderator: Thomas Wolfe, MD</i> <i>Moderator: Fawaz Al-Mufti, MD</i> <i>Moderator: Stephan Mayer, MD, FCCM, FNCS</i>
3:45 pm – 3:55 pm	Cortical Spreading Depression in Subarachnoid Hemorrhage – <i>David Chung, MD, PhD</i>
3:55 pm – 4:05 pm	BP Management of the Reperused Brain – <i>Fawaz Al-Mufti, MD</i>
4:05 pm – 4:15 pm	Novel management strategies for DCI post SAH – <i>Nick Morris, MD</i>
4:15 pm – 4:25 pm	BP Management Before Reperfusion – <i>Nils Peterson, MD, PhD, MSc</i>
4:25 pm – 4:35 pm	Q&A
<b>4:00 pm - 6:00 pm</b>	<b>GAPS Committee Meeting.....</b> <b>Gila Monster</b>
<b>4:35 pm – 5:40 pm</b>	<b>Complex Cases and Bail-Out Techniques .....</b> <b>Akimel 3 &amp; 4</b> <i>Moderator: Mikayel Grigoryan, MD</i> <i>Moderator: Priyank Khandelwal, MD</i>
4:35 pm – 4:45 pm	<i>Krishna Amuluru, MD</i>
4:45 pm – 4:55 pm	<i>Shripal Shah, MD</i>
4:55 pm – 5:05 pm	<i>Lila Sheikhi, MD</i>
5:05 pm – 5:15 pm	<i>Violiza Inoa, MD</i>
5:15 pm – 5:25 pm	<i>Sudeepta Dandapat, MD</i>
5:25 pm – 5:40 pm	Q&A
<b>5:40 pm – 6:40 pm</b>	<b>Diversity, Equity and Inclusion Reception –</b> <b>Sponsored by Cerenovus .....</b> <b>Coyote/Buzzard/Eagle</b> (Deer/Scorpion BackUp)
<b>7:00 pm – 10:00 pm</b>	<b>SVIN Black and White Gala (in celebration of S:VIN Journal Launch) –</b> <b>Sponsored Viz.ai .....</b> <b>Hemapik Lawn</b>





## Saturday, November 20

7:00 am – 8:00 am	<b>Breakfast .....</b> Akimel 3 & 4
7:00 am – 12:00 pm	<b>Registration &amp; Help Desk Open.....</b> Akimel Foyer
7:00 am – 3:30 pm	<b>Speaker Ready Room .....</b> Rattlesnake
8:00 am – 9:30 am	<b>Clinical Trials Update: Stroke &amp; Neurointerventional.....</b> Akimel 3 & 4 <i>Moderator: Sunil Sheth, MD</i> <i>Moderator: Amin Nima Aghaebrahim, MD</i>
8:00 am – 8:10 am	The SQUID Trial for the Embolization of the Middle Meningeal Artery for Treatment of Chronic Subdural Hematoma (STEM) – <i>David Fiorella, MD</i>
8:10 am – 8:20 am	TESLA – <i>Osama Zaidat, MD, FSVIN</i>
8:20 am – 8:30 am	SWIFT DIRECT – <i>Jan Gralla, MD</i>
8:30 am – 8:40 am	ENDOLOW – <i>Raul Nogueira, MD, FSVIN</i>
8:40 am – 8:50 am	STENTRODE First in Human Early Feasibility Study (SWITCH) – <i>Thomas Oxley, MD, PhD</i>
8:50 am – 9:00 am	ETCHES I (Cerevasce Shunt) – <i>Pedro Lylyk, MD</i>
9:00 am – 9:10 am	LUMOSA – <i>Thomas Devlin, MD, PhD, FSVIN</i>
9:10 am – 9:18 am	SVIN Registry – <i>Diogo Haussen, MD, FSVIN</i>
9:18 am – 9:30 am	Q&A
9:30 am – 10:45 am	<b>Endovascular + Vascular Neurology Joint Session 2 .....</b> Akimel 3 & 4 <i>Moderator: Guillermo Linares, MD</i> <i>Moderator: Dhruvil Pandya, MD, FAIHM, ABOIM</i>
9:30 am – 9:40 am	Management of Vertebral Stenosis – <i>Guillermo Linares, MD</i>
9:40 am – 9:50 am	Histotripsy Based Liquefaction and Drainage of ICH – <i>Aditya Pandey, MD</i>
9:50 am – 10:00 am	The Art of qMRA for Quantitative Flow Measurement – <i>Ali Alaraj, MD, FAHA, FACS</i>
10:00 am – 10:10 am	Migraine and Stroke - The Role of Endothelial Dysfunction – <i>Gretchen Tietjen, MD</i>
10:10 am – 10:20 am	Endovascular Treatment Management of CVST – <i>Fazeel Siddiqui, MD, FAHA</i>
10:20 am – 10:30 am	ICA - Is the Future in Vessel Wall Imaging – <i>Edgar Samaniego MD, MS, FAAN, FSVIN</i>
10:30 am – 10:45 am	Q&A
10:45 am – 11:00 am	<b>Coffee Break.....</b> Akimel Foyer
11:00 am – 12:00 pm	<b>Fellows Course – Didactic .....</b> Akimel 3 & 4 <i>Moderator: Mikayel Grigoryan, MD, FSVIN</i> <i>Moderator: Diogo Haussen, MD, FSVIN</i>
11:00 am – 11:20 am	The Need for SPEED: Stroke Process Efficiency and Effectiveness Driven Initiative – <i>Brijesh Mehta, MD, FSVIN</i>
11:20 am – 11:30 am	Radial Access in Neurointerventional Procedure: Part I: “Starting the Change” – <i>Mohammad El-Ghanem, MD</i>
11:30 am – 11:40 am	Radial Access in Neurointerventional Procedure: Part II – <i>Priyank Khandelwal, MD</i>
11:40 am – 11:55 am	First Case Experiences – <i>Diogo Hassan, MD, FSVIN, Mohammad El-Ghanem, MD, and Mikayel Grigoryan, MD</i>
11:55 am – 12:00 pm	Q&A
12:00 pm – 12:30 pm	<b>Fellows Course Lunch.....</b> Coyote/Buzzard/Eagle
12:30 pm – 3:30 pm	<b>Fellows Course – Hands-On .....</b> Kave Ballroom <i>Participating Industry Partners: Medtronic, MicroVention, Penumbra, Stryker, Cerenovus, and Balt</i>

# FACULTY

**Aaron Grossman, MD, PhD**  
University of Cincinnati Neuroscience Institute

**Aaron Rodriguez-Calienes, MD**  
Clinica Angloamericana

**Abbigayle Doerr, DNP, APRN, FNP-BC, ANVP-BC**  
Northwestern Medicine Central DuPage Hospital

**Aditya Pandey, MD**  
University of Michigan

**Afshin Divani, PhD, FAHA**  
University of New Mexico School of Medicine

**Alexandra Czap, MD**  
University of Texas Health Science Center at Houston

**Ali Alaraj, MD, FAHA, FACS**  
University of Illinois at Chicago – UI Health

**Alicia Castonguay, PhD, FAHA, FSVIN**  
University of Toledo

**Alicia Richardson, MSN, RN, ACCNS-AG**  
Penn State Health

**Alicia Zha, MD**  
Ohio State University

**Alisia Hindman, DNP, AGACNP, SCRNP**  
Methodist University Hospital

**Ameer Hassan, DO, FAHA, FSVIN**  
Valley Baptist Medical Center

**Amin Nima Aghaebrahim, MD**  
Baptist Health, Lyrerly Neurosurgery

**Amir Shaban, MD**  
University of Iowa Hospitals and Clinics

**Amrou Sarraj, MD**  
Case Western Reserve-University Hospitals  
Cleveland Medical Center

**Andrei Alexandrov, MD**  
University of Tennessee

**Andrew Demchuk, MD, FRCPc**  
University of Calgary

**Andrew Ducruet, MD**  
Barrow Neurological Institute

**Andrew Southerland, MD, MSc**  
University of Virginia, Departments of  
Neurology and Public Health Sciences

**Anne Alexandrov, MD, PhD, RN, AGACNP-BC, CCRN, NVRN-BC, ANVP-BC, FAAN**  
University of Tennessee Health Science Center at  
Memphis

**Ashutosh Jadhav, MD, PhD, FAHA, FSVIN**  
Barrow Neurological Institute  
Atilla Özcan Özdemir

**Atilla Özcan Özdemir, MD**  
Eskisehir Osmangazi University, Turkey

**Boris Pabon, MD**

**Brijesh Mehta, MD**  
Memorial Neuroscience Center

**Chintan Rupareliya, MD, MHA**  
University of Kentucky

**Christopher Kellner, MD**  
Mount Sinai Medical Center

**Conrad Liang, MD, PhD**  
Kaiser Permanente

**Cynthia Kenmuir, MD, PhD**  
University of Pittsburgh Medical Center

**David Chung, MD, PhD**  
Harvard Medical School and Massachusetts General  
Hospital

**David Fiorella, MD**  
Stony Brook University

**David Liebeskind, MD, FAAN, FAHA, FANA, FSVIN, FWSO**  
UCLA Medical Center

**Dhruvil Pandya, MD, FAIHM, ABOIM**  
Northwestern Central DuPage Hospital

**Dileep Yavagal, MD, MBBS, FSVIN, FAAN, FAHA**  
University of Miami Miller School of Medicine

**Diogo Haussen, MD, FSVIN**  
Emory University

**Donald Tucker, LP**  
Medical City Arlington (TX)

**Dorothea Altschul, MD, FSVIN**

**Edgar Samaniego, MD, MS, FAAN, FSVIN**  
University of Iowa Hospitals and Clinics

**Elissa Ortolani, MD**  
University of Pittsburgh School of Medicine

**Eloy Mansilla, MD**  
Servicio De Salud Metropolitano Sur and  
Clínica Alemana

**Esteban Cheng-Ching, MD**  
Premier Health Clinical Neuroscience Institute,  
Wright State University Boonshoft School of  
Medicine

**Eva Mistry, MBBS, MSCI**  
University of Cincinnati

**Evan Kolesnick, MS**  
Jefferson College of Public Health, Philadelphia  
College of Osteopathic Medicine (PCOM)

**Fawaz Al-Mufti, MD**  
Westchester Medical Center Health System

**Fazeel Siddiqui, MD, FAHA**  
University of Michigan Health - West

**Felipe Albuquerque, MD**  
Barrow Neurological Institute

**Gabor Toth, MD, FAHA**  
Cleveland Clinic Foundation

**Georgios Tsivgoulis, MD, PhD, MSc, FESO, FEAN, FAAN**  
University of Athens

**Gretchen Tietjen, MD**  
University of Toledo

**Guillermo Linares, MD**  
Saint Louis University

**James Grotta, MD**  
Memorial Hermann Hospital – Texas Medical Center

**James Siegler, MD**  
Cooper University Hospital

**Jan Gralla, MD**  
Leading Medicine Guide

**Jeffrey Saver, MD, FAHA, FAAN, FANA**  
UCLA Medical Center

**Jennifer Patterson, MSN, ACNP-BC, CCRN, FHM**  
CHI Memorial Stroke & Neuroscience Center

**Jenny Tsai, MDCM, FRCPC**  
Michigan State University College of Human  
Medicine

**Johanna Fifi, MD, FSVIN**  
Mount Sinai Health System

**Joseph Kass, MD, JD, FAAN**  
Baylor College of Medicine

**Joshua S. Catapano, MD**  
Barrow Neurological Institute

**Juan Vivanco-Suarez, MD**  
University of Iowa

**Juhana Frosen, MD, PhD**  
Tampere University

**Julie Shawver, PA-C**  
ProMedica Toledo Hospital

**Kaiz Asif, MD**  
AMITA Health

**Kara Sands, MD**  
Mayo Clinic

**Kaustubh Limaye, MD**  
Indiana University School of Medicine

**Krishna Amuluru, MD**  
Goodman Campbell Brain and Spine

**Lee Birnbaum, MD, MS**  
University of Texas Health – San Antonio

**Lila Sheikh, MD**  
University of Kentucky

**Lisa Rotenstein, MD**  
Brigham and Women's Hospital (Boston)

**Louise McCullough, MD, PhD**  
McGovern Medical School at UTHealth

**Lucas Eljovich, MD, FSVIN**  
Semmes-Murphy Neurologic & Spine Institute



**Mahmoud R. Mohammaden, MD, MSc**  
Emory University

**Marc Ribó, MD**  
Hospital Vall d'Hebron

**Mario Martinez-Galdamez, MD**

**Marta Olive-Gadae, MD**  
Hospital Universitari Vall d'Hebron (Barcelona)

**Matthew J. Gounis, PhD**  
University of Massachusetts Medical School

**Maxim Mokin, MD**  
University of South Florida

**May Nour, MD**  
UCLA Medical Center

**Mesha Martinez, MD**  
Indiana University School of Medicine,  
Riley Hospital for Children

**Michael Chen, MD**  
Rush University Medical Center

**Michael Lawton, MD**  
Barrow Neurological Institute

**Mikayel Grigoryan, MD**  
Glendale Adventist Medical Center

**Mohammad El-Ghanem, MD**  
HCA Northwest Medical Center

**Mohammad Jumaa, MD, FAHA, FSVIN**  
ProMedica Stroke Network

**Mohamed Teleb, MD**  
Banner Health

**Mudassir Farooqui, MD, MPH**  
University of Iowa Hospitals and Clinics

**Nabeel Herial, MD**  
Thomas Jefferson University

**Nandakumar Nagaraja, MD, MS, FAHA**  
Penn State Health Milton S. Hershey  
Medical Center

**Natalia Perez de la Ossa, PhD**  
Germans Trias Hospital

**Nelson Maldonado, MD**

**Nicholas M. Mohr, MD, MS**  
University of Iowa Carver College of Medicine

**Nicholas Morris, MD**  
University of Maryland School of Medicine &  
University of Maryland Medical Center

**Nicole Gonzales, MD**  
University of Colorado School of Medicine

**Nils Peterson, MD, PhD, MSc**  
Division of Neurocritical Care and Emergency  
Neurology at Yale School of Medicine & Yale New  
Haven Hospital

**Nina Moore, MD**  
Cleveland Clinic

**Oana Dumitrascu, MD, MSc, FANOS**  
Mayo Clinic College of Medicine and Science

**Pankajavalli Ramakrishnan, MD, PhD**  
Riverside Regional Medical Center

**Paul E. Pepe, MD, MPH, FAEMS, MCCM, MACP**  
Dallas County Emergency Medical Services, Dallas  
(TX), University of Texas Health Sciences Center,  
Houston (TX), University of Miami, Miami (FL),  
Metropolitan EMS Medical Directors Global Alliance,  
Dallas (TX), Global Emergency Medical Support, Ft.  
Lauderdale (FL)

**Pedro Lylyk, MD**  
Clinica La Sagrada Familia

**Priyank Khandelwal, MD**  
University of Miami

**Randall Edgell, MD, FSVIN**  
Saint Louis University

**Raul Nogueira, MD, FSVIN**  
Emory University

**Robin Novakovic-White, MD, FAHA, FSVIN, FAAN**  
UT Southwestern Medical Center

**Osama Zaidat, MD, MS FSVIN, FAHA**  
St. Vincent Mercy Hospital

**Samarth Shah, PharmD, BCPS**  
UW Health

**Sandra Narayanan, MD, FAHA, FANA, FSVIN**  
University of Pittsburgh School of Medicine

**Santiago Ortega-Gutierrez, MD MSc, FAHA, FSVIN**  
University of Iowa Hospitals and Clinic

**Satoshi Tateshima, MD**  
UCLA Medical Center

**Shashvat Desai, MD**  
Honor Health

**Shripal Shah, MD**  
Arihant Neurocenter, Shraddha Hospital

**Shuichi Suzuki, MD, PhD**  
UC Irvine

**Skye Coote, NP, CCRN, MN, ANVP-BC, NVRN-BC**  
Melbourne Health – Melbourne Brain Centre at the  
Royal Melbourne

**Stavropoula Tjoumakaris, MD, FAANS, FAHA**  
Thomas Jefferson University Hospital at Sidney  
Kimmel Medical College

**Stephan Mayer, MD, FCCM, FNCS**  
Westchester Medical Center Health Network

**Steve Warach, MD, PhD**  
Seton Dell Medical School Stroke Institute,  
Ascension Texas

**Sudeepta Dandapat, MD**  
Aurora Neurosciences Innovation Institute,  
St. Luke's Hospital

**Sujan Reddy, MD, MPH**  
Mercy Clinic Hospital – Fort Smith

**Sunil Sheth, MD**  
UT Health McGovern School of Medicine

**Syed Zaidi, MD**  
ProMedica Physicians Group

**Thanh Nguyen, MD, FRCPC, FSVIN, FAHA**  
Boston Medical Center, Boston University School  
of Medicine

**Thomas Devlin, MD, PhD, FSVIN**  
University of Tennessee Health Science Center

**Thomas Fischer**  
Angels Initiative, Boehringer-Ingelheim

**Thomas Oxley, MD, PhD**  
Mount Sinai Health System

**Thomas Wolfe, MD**  
Advocate Aurora, St. Luke's Medical Center

**Todd Abruzzo, MD, FAHA**  
University of Arizona and Mayo Clinic Colleges of  
Medicine, Barrow Neurological Institute at Phoenix  
Children's Hospital, and Ira A. Fulton School of  
Engineering

**Tudor Jovin, MD, FSVIN**  
UPMC Stroke Institute

**Victor Urrutia, MD, FAHA**  
Johns Hopkins University School of Medicine

**Vikram Huded, MD**  
Narayana Health Institute of Neurosciences

**Viktor Szeder, MD, PhD, MSc**  
UCLA Medical Center

**Violiza Inoa, MD**  
Semmes-Murphy Clinic

**Vitor Mendes Pereira, MD, MSc**  
St. Michael's Hospital

**Wade Smith, MD, PhD**  
UCSF Weill Institute for Neurosciences

**Waldo Guerrero, MD**  
University of South Florida

**Zongrong Miao, MD**



# AWARDS AND RECOGNITION



## 2021 SVIN Officers List

**President**  
David Liebeskind, MD, FAHA, FAAN, FSVIN

## Incoming President

Ameer E. Hassan, DO, FAHA, FSVIN

## Treasurer

Santiago Ortega-Gutierrez, MD, MSc, FSVIN

## Secretary

Thanh Nguyen, MD, FSVIN

## Immediate Past President

Italo Linfante, MD, FAHA, FSVIN

## Board of Directors

Diogo Haussen, MD, FSVIN  
Vallabh Janardhan, MD, FAHA, FAAN, FSVIN  
Amer Malik, MD, MBA, FSVIN  
Ossama Mansour, MD, FSVIN  
Jawad F. Kirmani, MD, FSVIN  
Robin Novakovic-White, MD, FSVIN, FAHA, FAAN  
Sunil Sheth, MD, FSVIN  
Fawaz Al-Mufti, MD  
Gabor Toth, MD, FAHA

## Ex-Officio

Raul Nogueira, MD, FSVIN  
Dileep R. Yavagal, MD, FAHA, FSVIN  
Osama Zaidat, MD, MS FSVIN, FAHA  
Tudor Jovin, MD, FSVIN

**SVIN would like to extend a special thank you to the following individuals for their contributions to the SVIN 2021 Meeting:**

**Chair:** Santiago Ortega-Gutierrez, MD, MSc, FSVIN

**Vice Chair:** Sunil Sheth, MD, FSVIN  
Alicia Castonguay, PhD, FSVIN, FAHA  
Ameer Hassan, DO, FAHA, FSVIN  
Anne W. Alexandrov, PhD, AGACNP-BC, CNS, CCRN, ANVP-BC  
Andrei Alexandrov, MD  
Edgar Samaniego, MD, FSVIN  
Maxim Mokin, MD  
May Nour, MD  
Violiza Inoa, MD  
Kaiz Asif, MD  
Mohammad Jumaa, MD, FSVIN  
Thanh Nguyen, MD, FSVIN  
Cynthia Kenmuir, MD  
Fawaz Al-Mufti, MD  
Jay Dolia, MD  
Amin Aghaebrahim, MD  
Natalia Perez de la Ossa, MD  
Elissa Ortolani, MD  
Julie Shawver, MD  
Mikayel Grigoryan, MD  
Diogo Haussen, MD, FSVIN  
Priyank Khandewal, MD  
Mohammad El-Ghanem, MD

## 2021 Fundraising Committee Members

**Chair:** Santiago Ortega-Gutierrez, MD, MSc, FSVIN  
David Liebeskind, MD, FAHA, FSVIN, FWSO  
Ameer E. Hassan, DO, FAHA, FSVIN  
Thanh Nguyen, MD, FSVIN  
Italo Linfante, MD, FSVIN  
Sunil Sheth, MD, FSVIN

## 2021 Abstract Committee Members

**Chair:** Alicia Castonguay, PhD, FSVIN, FAHA  
Michael Abraham, MD, FAHA  
Mehdi Bouslama, MD  
Alexandra Czap, MD  
Shashvat Desai, MD  
Camilo Gomez, MD  
Gurmeen Kaur, MD  
Ossama Mansour, MD, PhD, FNR, EBNRcet, FSVIN  
Maxim Mokin, MD  
Thanh Nguyen, MD, FSVIN  
Santiago Ortega-Gutierrez, MD, MSc, FSVIN  
Robert Taylor, MD  
Mohamed Teleb, MD

## 2021 Award Winners for Program

### Innovation Award:

Thomas Oxley, MD, PhD

### Distinguished Service Award:

David Liebeskind, MD, FAHA, FSVIN, FWSO

### Pilot Grant Awardees:

1. Trainee: Hassan Nour, MD  
Dysfibrinogenemia as a Predictor of Intracerebral Hemorrhage following Mechanical Endovascular Revascularization
2. Trainee: Robert Regenhart, MD, PhD  
Infarct growth despite thrombectomy for large vessel occlusion stroke
3. Junior: Alexandra Czap, MD  
Optimizing Management and Outcomes of Large Vessel Occlusion Ischemic Stroke Utilizing Mobile Stroke Units (LVO-MSU)
4. Junior: James Ho  
Vascular Regeneration for Endovascular Treatment of Aneurysm
5. Senior: Thanh Nguyen, MD & Raul Nogueira, MD, FSVIN  
Global impact of the COVID-19 pandemic on stroke care: 1-year follow-up study

### FSVIN:

Michael Abraham, MD, FAHA, FSVIN  
Dorothea Altschul, MD, FSVIN  
Kaiz Asif, MD, FSVIN  
Mikayel Grigoryan, MD, FSVIN  
Cynthia Kenmuir, MD, PhD, FSVIN  
Radoslav Raychev, MD, FSVIN  
Viktor Szeder, MD, PhD, MSc, FSVIN  
Syed Zaidi, MD, FSVIN

### Best Abstract Award Recipient:

Alexandra Czap, MD  
Mobile Stroke Unit Process Metrics in Large Vessel Occlusion Stroke Patients: BEST-MSU Substudy

### Young Investigator Recipient:

Shashvat Desai, MD  
Incidence and predictors of delayed functional independence in the TREVO retriever registry

## 2021 Trainee Travel Grant Awardees:

A T M Hasibul Hasan	Marwa Elnazair
Aayushi Garg	Matthew Kole
Abubakar Siddique	Mehdi Bouslama
Adnan Mujanovic	Michael David Modzelewski
Ahmad Ballout	Michael Nahhas
Alexander Sidor	Milagros Galecio-Castillo
Ammad A Baig	Mohamed Fahmy Doheim
Amol Mehta	Mohamed Shehab-Eldin
Andrés Catalá	Mohammad Kayyali
Aravind Reddy	Neil Suryadevara
Ashutosh Mahapatra	Pouria Moshayedi
Carlos De la Garza	Praveen Hariharan
Chintan Rupareliya	Rahul Chandra
Cynthia B. Zevallos Mau	Rahul Rao
David Rosenbaum-HaLevi	Rami Fakhri
Haris Kamal	Rami Morsi
Harish Chandrappa	Shahvaiz Magsi
Hassan Aboul Nour	Shail Thanki
Ivo Bach	Sitara Koneru
Javier Alfredo Lagos-Servellon	Sonam Thind
Juan Carlos Martinez Gutierrez	Steven David Shapiro
Kunakorn Atchaneeayasakul	Taha Nisar
Laura Sanchez Garcia	Tigran Khachatryan
Liqi Shu	Vera Sharashidze
Mahmoud Mohammed	Yazan Radaideh

## SVIN TOP SUPPORTERS

SVIN gratefully acknowledges the generous support from our sponsors:

### DIAMOND LEVEL



CERENOVUS  
PART OF THE Johnson & Johnson FAMILY OF COMPANIES

Medtronic  
Further Together

Penumbra

stryker

### PLATINUM LEVEL

MicroVention®  
TERUMO

iz.ai

### GOLD LEVEL

balt  
inspiring innovation

### BRONZE LEVEL

ALEXION

SCIENTIA

Imperative  
CARE

Genentech  
A Member of the Roche Group

SIEMENS

## Endorsements

The following organizations endorse the SVIN 14th Annual Meeting:



SNIS  
Society of Neurointerventional Surgery

- AMERICAN SOCIETY OF NEUROIMAGING
- ASSOCIATION OF NEUROVASCULAR CLINICIANS
- SOCIETY OF NEUROINTERVENTIONAL SURGERY
- WORLD FEDERATION OF INTERVENTIONAL AND THERAPEUTIC NEURORADIOLOGY

# EXHIBITOR LISTING

## Exhibit Hall Hours | Akimel 1 & 2

Wednesday, November 17 ..... 12:00 pm – 6:15 pm MST  
 Thursday, November 18 ..... 10:00 am – 4:00 pm MST  
 Friday, November 19 ..... 9:30 am – 4:00 pm MST

### Alexion Pharmaceuticals | Booth 512

121 Seaport Blvd  
 Boston, MA 02210  
 P: (475) 230-2596  
 W: [www.alexion.com](http://www.alexion.com)



Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. As a leader in rare diseases for nearly 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.

### Allm | Booth 305

125 Cambridgepark Drive, #301  
 Cambridge, MA 02140  
 P: (857) 209-5065  
 E: [getintouch@allmgroup.net](mailto:getintouch@allmgroup.net)  
 W: [www.allm.us](http://www.allm.us)



ALLM offers a proven next-generation mobile healthcare (mHealth) JOIN technology platform which facilitates seamless clinical communication, collaboration, and decision support for hospitals, providers, and coordinators along the patient journey and across sites and departments. Our digital solutions enhance patient safety and treatment outcomes, cuts systemic costs and liability, creates new patients access, and reduces clinician burnout, especially NIRs / neurosurgeons, and administrative hassles.

Our innovative mobile apps (HIPAA compliant and FDA approved) serve as workflow solutions to care providers for time-critical medical conditions in patient assessment, AI routing, pre-notification, care coordination, image sharing, telehealth/telemedicine, and robust data collection for clinical research and metrics.

### AstraZeneca | Booth 607

1800 Concord Pike  
 Wilmington, DE 19803  
 P: (714) 403-3087  
 E: [Benjamin.wu1@astrazeneca.com](mailto:Benjamin.wu1@astrazeneca.com)  
 W: <https://www.astrazeneca-us.com/>



AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology; Cardiovascular, Renal & Metabolism; and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit <https://www.astrazeneca-us.com/> and follow us on Twitter @AstraZenecaUS.

### Balt USA | Booth 609

P: (949) 788-1443  
 E: [customerservice@balt-usa.com](mailto:customerservice@balt-usa.com)  
 W: [balt-usa.com](http://balt-usa.com)



Balt USA LLC was established in 2017 as the US-based division of Balt Incorporated and is based in Irvine, California. Balt USA's focus is on the commercialization of Balt products in the United States as well as continuing a tradition of physician inspired innovation through novel research and development.

### Biomodex | Booth 606

300 Crown Colony Dr., Suite 504,  
 Quincy, MA 02169, USA  
 P: (813) 468-8086  
 E: [billperusek@biomodex.com](mailto:billperusek@biomodex.com)  
 W: [www.biomodex.com](http://www.biomodex.com)



BIOMODEX is a Boston and Paris-based medical technology company whose mission is to transform the way physicians train and rehearse procedures. The company 3D prints anatomical models using advanced materials that provide bio-realistic haptic feedback. The next-generation bio-realistic haptic simulators are fully customizable and integrate with a patented blood flow system and intraprocedural imaging tools such as TEE and ICE, enabling clinicians to gain life-like experience to advance skill sets and promote the adoption of new medical devices or techniques in their pursuit of improving patient outcomes. For more information on Biomodex's bio-realistic haptic simulators visit [www.biomodex.com](http://www.biomodex.com).

### Cerenovus | Booth 200

31 Technology Drive  
 Irvine, CA 92618  
 W: [www.cerenovus.com](http://www.cerenovus.com)



CERENOVUS, part of the Johnson & Johnson Medical Devices Companies, is a global leader in neurovascular care. Our commitment to changing the trajectory of stroke is inspired by our long heritage and dedication to helping physicians protect people from a lifetime of hardship. CERENOVUS offers a broad portfolio of devices used in the endovascular treatment of hemorrhagic and ischemic stroke.

### Corazon, Inc. | Booth 605

5000 McKnight Rd, Suite 300  
 Pittsburgh, PA 15237  
 P: (412) 364-8200  
 E: [mhartman@corazoninc.com](mailto:mhartman@corazoninc.com)  
 W: <https://corazoninc.com/>



Corazon is a national leader in program development for the Heart, Vascular, Neuroscience, Spine, and Orthopedic service lines. Corazon offers a full continuum of Consulting, Accreditation, Peer Review, Recruitment, and Interim Management services to provide the strategic, clinical, operational, market, and financial expertise necessary to help clients reach their highest growth potential.

### Cordis | Booth 610

14201 N.W. 60th Avenue  
 Miami Lakes, FL 33014  
 P: (800) 327-7714  
 E: [exhibits@cordis.com](mailto:exhibits@cordis.com)  
 W: [www.cordis.com/en\\_us](http://www.cordis.com/en_us)



Cordis is a worldwide leader in the development and manufacturing of interventional vascular technology with a more than 60-year history of pioneering products to treat millions of patients. With a reputation for clinical acumen, training and services, Cordis established a legacy of innovation in high-quality and less-invasive cardiovascular products and built a strong global footprint with operations in countries around the world.

### CSL Behring | Booth 500

W: [www.cslbehring.com](http://www.cslbehring.com)



Leading the Way on Serious & Rare Diseases

We are a global biotechnology leader focused on serving patients' needs. Our scientists use the latest technologies to develop and deliver innovative therapies that are used to treat serious and rare diseases, including immunodeficiency and autoimmune diseases, hereditary and acquired bleeding disorders, chronic inflammatory demyelinating polyneuropathy (CIDP), hereditary angioedema (HAE), and Alpha 1 antitrypsin deficiency, as well as transplantation and critical care.

### Imperative Care | Booth 504

1359 Dell Avenue  
 Campbell, CA 95008  
 P: (669) 235-8155  
 E: [imperative@imperativecare.com](mailto:imperative@imperativecare.com)  
 W: <https://imperativecare.com/>



Imperative Care is a medical technology company focused on developing the next generation of innovative solutions to address the vast and urgent unmet needs in stroke. The Zoom Stroke Solution™ offers a complete stroke system from access through reperfusion for fast and effective clot removal in a wide range of vessels. The system includes the Zoom™ 88 Large Distal Platform™ for neurovascular access, four vessel-matched Zoom Aspiration Catheters, and the powerful Zoom Pump and accessories. All Zoom catheters feature the TRX™ Tip which provides 15% greater clot engagement area at the tip of the catheter. #ElevatingStrokeCare

### Medtronic | Booth 513

5290 California Ave  
 Irvine, CA 92617  
 P: (800) 633-8766  
 W: <http://www.medtronic.com/nv>



We lead global healthcare technology, boldly attacking the most challenging problems. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 90,000+ people, and our technologies transform the lives of two people every second, every hour, every day. Expect more from us. Medtronic. Engineering the extraordinary.

### MicroVention | Booth 300

35 Enterprise  
 Aliso Viejo, CA 92656  
 P: (714) 247-8000  
 E: [hello@microvention.com](mailto:hello@microvention.com)  
 W: [www.microvention.com](http://www.microvention.com)



MicroVention-Terumo provides a complete approach to neuroendovascular technologies and currently consists of four main product groups: Aneurysm Therapy, Ischemic Stroke and Carotid Artery Disease, Neurovascular Malformations, and Access Product Solutions. Our extensive product lines allow our customers to uniquely address and customize the needs of their patients to provide a meaningful improvement in their lives.

Looking toward the future, we are committed to excellence in everything we do, and we strive to continually improve and innovate to provide our customers the finest technology available for their patients and are dedicated to achieving results that exceed expectations.

### Neurocoverage | Booth 510

119 Carriage Ct  
 Plymouth Meeting, PA 19462  
 P: (267) 685-6464  
 E: [info@neurocoverage.com](mailto:info@neurocoverage.com)  
 W: [www.neurocoverage.com](http://www.neurocoverage.com)



Neurocoverage offers neurointerventionalists exciting opportunities in the field with flexible coverage options, competitive salary and traveling opportunities. We provide full service neurovascular coverage to hospitals across the country. As a company founded and led by neurointerventionalists, we understand just how demanding the neurovascular field is. With a physician centered focus, Neurocoverage strives to create an environment where neurointerventionalists may work according to their availability, allowing for a more meaningful work-life balance. We also provide full malpractice coverage, assist in obtaining medical licenses for 50 states and Interstate Medical Licensure Compact (IMLC) at no cost to physicians. Learn more: [neurocoverage.com](http://neurocoverage.com)

# EXHIBITOR LISTING

## NovaSignal | Booth 611

2440 S Sepulveda Blvd  
Los Angeles, CA 90064  
P: (877) 638-7251  
E: info@novasignal.com  
W: www.novasignal.com



NovaSignal is a medical technology and data company that is revolutionizing transcranial Doppler ultrasound through the application of robotics, artificial intelligence, and cloud computing. The NovaSignal Platform, including the FDA cleared NovaGuide 2 Intelligent Ultrasound and cloud-based NovaGuide View, assesses cerebral hemodynamics in real time to support physicians in their clinical decision making.

## Patronus Neurology | Booth 304

5220 Jimmy Lee Smith Pkwy, Suite 104-265  
Hiram, GA 30141  
P: (800) 784-3104  
E: info@patronusneurology.com  
W: www.patronusmedical.com



Patronus Neurology provides elite 24 x 7 x 365 comprehensive emergency teleneurology solutions to hospitals and stand-alone ERs for any neurological question in an emergency setting. Our industry-leading response times put patients in contact with vascular-trained neurologists - not a call center or staging clinician - in under two minutes.

## Penumbra | Booth 511

One Penumbra Place  
Alameda, CA 94502  
P: (510) 748-3200  
E: info@penumbrainc.com  
W: www.penumbrainc.com



Penumbra, Inc., headquartered in Alameda, California, is a global healthcare company focused on innovative therapies. Penumbra designs, develops, manufactures and markets novel products and has a broad portfolio that addresses challenging medical conditions in markets with significant unmet need. Penumbra supports healthcare providers, hospitals and clinics in more than 100 countries.

## Phenox Inc. | Booth 404

9842 Research Drive  
Irvine, CA 92618  
P: (844) 674-3669  
E: cs@phenox.com  
W: www.phenox.com/usa



Since its founding in 2005, Phenox has been dedicated to developing innovative, breakthrough and clinically proven technologies and solutions for the treatment of neurovascular diseases. Phenox's products are used by endovascular specialists to treat ischemic and hemorrhagic stroke. More information about the company and its products can be found at [www.phenox.com](http://www.phenox.com).

## Q'Apel Medical | Booth 508

46708 Lakeview Blvd.,  
Fremont, CA 94538  
P: (510) 738-6255  
E: info@qapelmedical.com  
W: <https://qapelmedical.com/>



In the simplest sense, we're a company that creates solutions. More specifically, we design novel access device technology for vascular interventions and unmet clinical needs. Because in the precious seconds that surround a stroke emergency, clinicians need technology that delivers. That's where we come in.

## Rapid AI | Booth 400

405 El Camino Real, Suite 601  
Menlo Park, CA 94025  
P: (650) 388-9767  
E: info@rapid.ai  
W: www.rapidai.com



RapidAI is the global leader using AI to combat life-threatening neurovascular conditions. From home to hospital and ER to OR, RapidAI is leading the next evolution of clinical decision-making and patient workflow, bringing the end-to-end patient journey into focus. Based on intelligence gained from over 2 million scans the Rapid® platform transforms care coordination, offering care teams a level of patient visibility never before possible, saving lives, time and money.

The Rapid portfolio of products includes Rapid Aneurysm, Rapid ICH, Rapid ASPECTS, Rapid CTA, Rapid LVO, Rapid CTP, Rapid for Angio, Rapid MRI, Rapid Workflow for Stroke, Rapid for Prehospital, and Rapid Insights.

## Rapid Medical | Booth 201

1355 Shotgun Road  
Sunrise, FL 33326  
P: (954) 884-2120  
E: infousa@rapid-medical.com  
W: www.rapid-medical-us.com



Rapid Medical is developing game-changing devices for neurovascular treatments. Rapid Medical is the maker of FDA approved COMANECI, the first-ever controllable aneurysm neck-bridging device and TIGERTRIEVER, the first-ever controllable, fully visible stentriever that is designed to treat ischemic stroke patients. The TIGERTRIEVER is an investigational device in the US.

## Scientia Vascular LLC | Booth 101

3487 W 2100 South Suite 100  
West Valley, UT 84119  
P: (888) 385-9016  
E: Sales@scientiavascular.com  
W: www.scientiavascular.com



Scientia Vascular is a dynamic and rapidly growing company developing and commercializing differentiated technologies that facilitate vascular access. Scientia delivers therapeutic solutions for a wide-range of vascular procedures, including stroke and peripheral embolization and has gained strong customer adoption in just a few years since commercial introduction. By adopting a first-principles approach, we collaborate with physician thought-leaders to develop innovative medical devices and therapies that are unconstrained by conventional design and optimized to address the evolving needs of interventional specialists.

## Sevoro Health | Booth 604

575 Lexington Ave 4th Floor  
New York, NY 10022  
P: (866) 239-1650  
E: Branden@sevoro.com  
W: www.sevoro.com



Sevoro is revolutionizing and personalizing teleneurology with one goal: to enable hospitals to enhance stroke care and save lives. Sevoro OneCall™ technology connects hospital staff directly to an on-call vascular neurologist in 45 seconds, eliminating call centers, and saving time when time is everything. Sevoro's singular, relentless focus on teleneurology and doing it better (and faster) than anyone had ever dreamed has resulted in the industry's fastest response, imaging review, and door-to-needle times, and the very best patient outcomes. Sevoro is a physician-led organization with an unwavering commitment to providing actionable data, and to treating partners and patients like family.

## Siemens | Booth 608

40 Liberty Boulevard  
Malvern, PA 19355, USA  
P: (610) 209-1045  
E: linda.gallant@siemens-healthineers.com  
W: <https://www.siemens-healthineers.com/en-us>



Siemens Healthineers AG is shaping the future of healthcare. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers enables healthcare providers worldwide to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving the patient experience, and digitalizing healthcare. Further information is available at [www.siemens-healthineers.com](http://www.siemens-healthineers.com).

## Sim & Cure Inc. | Booth 612

P: 917-209-0399  
E: r.renteria@sim-and-cure.com  
W: <https://sim-and-cure.com/>



Sim&Cure, headquartered in the thriving medtech environment of Montpellier, France, is a global company that pioneers, amongst other products, a patient-based computational model for brain aneurysm treatment. Sim&Size™ provides personalized and clinically accurate computational modeling to facilitate the selection and placement of medical devices. With over 7000 successful cases in over 400 hospitals Sim&Size™ delivers value worldwide.

The US division is headquartered in New York and has a team spread across the country ready to assist you. They can be reached at [r.renteria@sim-and-cure.com](mailto:r.renteria@sim-and-cure.com) or on 917.209.0399. Our website is <https://sim-and-cure.com/>

## Spartan Micro | Booth 204

3184 Airway Ave.  
Costa Mesa, CA 92626  
P: (512) 270-8501  
E: info@spartanmicro.com  
W: www.spartanmicro.com



Spartan Micro is a neurovascular company that designs, develops, manufactures, and markets innovative medical devices. We focus on the neurovascular market for the safe endovascular treatment of common, and uncommon, cerebrovascular diseases and abnormalities.

## Stryker | Booth 301

47900 Bayside Parkway  
Fremont, CA 94538  
P: (510) 413-2400  
E: nvmarcom@stryker.com  
W: <https://www.stryker.com/us/en/portfolios/neurotechnology-spine/neurovascular.html>



Stryker's Neurovascular division is focused on advancing the practice of less invasive stroke therapies through its Complete Stroke Care solutions. It is dedicated to providing innovative stroke products and services for ischemic and hemorrhagic stroke, and is committed to providing clinical education and support to help physicians deliver better patient outcomes

## Viz.ai | Booth 503

1819 Polk St,  
San Francisco, CA 94109  
P: (866) 849-4980  
E: hello@viz.ai  
W: www.viz.ai



Viz.ai is the leader in AI-driven intelligent care coordination. Viz.ai's mission is to fundamentally improve how healthcare is delivered in the world, through intelligent software that promises to reduce time to treatment, improve access to care, and increase the speed of diffusion of medical innovation.



## Become a Member of **SVIN** Today!

The Society of Vascular and Interventional Neurology (SVIN) was created to achieve the highest level of care for patients through increased collaboration in scientific research and by educating young professionals and training young investigators. The Society also aims to provide opportunities to connect leaders in the field and provide a common ground for dialogue and creation of practice and safety standards.

By joining our member network within SVIN, you become connected with an elite group of premier neurologists, hospitalists, and other healthcare professionals in the fields of vascular and interventional neurology. SVIN also offers education and training opportunities, the field (CME credits available), networking at collaborative SVIN Events and Conferences, and opportunities to get involved with SVIN committees and taskforces.

### **SVIN Membership Benefits Include:**

- Discounted SVIN Meeting Rates at SVIN's Annual Conference and Bi-Annual SVIN Break Event.
- Access to the Member Directory of SVIN.
- Free online privileges to view exclusive webinars, such as WebNIR Tutorials.
- Free subscription to the society's newsletter, The Core.
- Complimentary Job and Fellowship Postings on our website.
- Publishing opportunities in the Stroke: Vascular and Interventional Neurology Journal, the official Journal of SVIN
- Archived materials from past meetings and webinars.
- Patient Resources & Research Information.
- Voting rights within the society.
- Volunteer Opportunities within SVIN's 15 committees, sub-committees and taskforces

Visit [www.svin.org](http://www.svin.org) for details on how to join or email us at [info@svin.org](mailto:info@svin.org).

---

## Apply for **FSVIN**!

The Society of Vascular and Interventional Neurology (SVIN) offers an elevated member status of Fellow of Society of Vascular and Interventional Neurology (FSVIN), the SVIN's esteemed category of membership. Fellow status recognizes exceptional service and contribution to the Society, academic excellence, and leadership in the field of Vascular and Interventional Neurology. Individuals who meet the requirements of this elevated membership status will add the letters, FSVIN, to their respective titles. You may become a Fellow of Society of Vascular and Interventional Neurology (FSVIN) using one of the following routes:

- Active SVIN members may apply for the FSVIN membership if they have attended at least 5 SVIN Annual Meetings and have been a SVIN member for a minimum of 7 consecutive years. Additional criteria and application information can be found on [www.svin.org](http://www.svin.org) or provided upon request by emailing [info@svin.org](mailto:info@svin.org).
- Current FSVIN members may nominate Active members of SVIN for the fellow of SVIN status if the nominee meets the criteria outlined above and on [www.svin.org](http://www.svin.org).
- SVIN Board of Directors members are granted FSVIN membership due to their contributions of time, effort, and thoughtful leadership to the Society during their term(s) of service.

Visit [www.svin.org](http://www.svin.org) to learn more.



# FOLLOW US ON SOCIAL MEDIA – #SVINAM

Ways to connect with  
us via social media  
to submit a topic or  
start a discussion:

Post, pin, like  
and share your  
annual meeting  
experience on FB

Tweet, retweet,  
follow and use  
#SVIN2021 on  
Twitter

Invite us to your  
Linkedin network

Visit the  
Registration Desk  
to learn more

Contact the SVIN  
Executive office at  
info@svin.org to  
share your success  
story or a patient  
testimonial

 SVIN - Society of Vascular  
and Interventional Neurology

 facebook.com/SVINonline

 @svinsociety



**Scaling healthcare globally to increase access to stroke  
& mechanical thrombectomy through collaboration.**



**MT2020+**  
Mission Thrombectomy



FOR MORE INFORMATION GO TO MISSIONTHROMBECTOMY2020.ORG

# WHY YOU SHOULD JOIN



## SVIN Membership Perks

- **FREE** access to exclusive webinars, the society's newsletter and the *Stroke: Vascular and Interventional Neurology Journal*.
- **DISCOUNTED** pricing on SVIN Memberships, the online ASES/BSES education courses (CME attached), Annual Meeting and SVIN Break registration, and more!
- **FELLOWSHIP & NETWORKING** opportunities as well as complimentary job and fellowship postings.
- Participation in **GLOBAL** SVIN initiatives.

## DISCOUNTS & PRICING

SVIN offers significant discounts for its international members based on World Bank pricing.

## SVIN HOSTS A MULTITUDE OF EVENTS THROUGHOUT THE YEAR SUCH AS:

- WebNIR Tutorials
- SVIN Break Bi-Annual Conference
- SVIN Annual Meeting
- & More!



For assistance, please contact the  
SVIN Executive Office via email [info@SVIN.org](mailto:info@SVIN.org).



# GET INVOLVED WITH SVIN!

---

If you would like to get more involved with SVIN, please contact [info@svin.org](mailto:info@svin.org) and indicate your area of interest!







## Sponsored Symposium

Friday, November 19, 2021 • 12:00 -12:35 MST • Akimel 3-4



### Early Clinical Experience with BOBBY™: A New Generation Balloon Guide Catheter

**Bharathi D. Jagadeesan, MD**

University of Minnesota Medical Center,  
M Health Fairview, Minneapolis, MN, USA



### Flow Redirection Endoluminal Device (FRED™) for Treatment of Intracranial Aneurysms: A Systematic Review

**Jason M. Davies, MD, PhD**

Gates Vascular Institute,  
Buffalo, NY, USA

#### Indications for Use on file at MicroVention.


RX Only: Federal (United States) law restricts this device to sale by or on the order of a physician. MicroVention, BOBBY and FRED are registered trademarks of MicroVention, Inc. in the United States and other jurisdictions. Refer to Instructions for Use, contraindications and warnings for additional information. ©2021 MicroVention, Inc. 10/21.

## The Comprehensive AI Solution for Vascular Interventional Neurologists



### Viz LVO

Reduce DIDO and DTG Times.  
Reimbursed by CMS



### Viz ANX

Background Aneurysm Screening  
Across the Entire Population  
Not available for sale within the US.

Now 510K Pending!



### Viz ICH

Supporting Minimally Invasive  
ICH Research and ICH Care



### Viz SDH

Supporting MMA  
Embolization Research  
Investigational use only. Not for sale in the US.




# IMPROVING PATIENT CARE IN BRAIN ANEURYSM TREATMENT

STAND  
612/614

Proven clinical  
impact\*

FDsize is safe,  
fast & accurate

FDsize improves  
& facilitates flow  
diverter sizing in  
clinical routine



Sim&Size  
TO IMPROVE THERAPEUTIC PLANNING

**Efficiency, safety, and reproducibility**  
in neurovascular treatment that's  
adjusted to each patient's needs



Prowler<sup>®</sup>EX  
Microcatheter









©CERENOVUS 2021. All rights reserved. 180349-210617

# RED<sup>TM</sup>

## REPERFUSION CATHETERS

62

68

72

.062" ID 138 cm

.068" ID 132 cm

.072" ID 132 cm

1.93 mm (.076") OD

2.13 mm (.084") OD

2.16 mm (.085") OD

Photographs taken by and on file at Penumbra, Inc. Please contact your local Penumbra representative for more information.  
Copyright ©2021 Penumbra, Inc. All rights reserved. The Penumbra P logo, RED, and Penumbra System are registered  
trademarks or trademarks of Penumbra, Inc. in the USA and other countries. 22073, Rev. A 09/21 USA

Penumbra System®


[www.penumbrainc.com](http://www.penumbrainc.com)




Medtronic

Let's go  
beyond


Together, we can  
**break new ground** in  
**neurovascular** treatment.



Pipeline™ Flex  
Embolization Device with  
Shield Technology™



Rist™  
Radial Access System



Solitaire™ X  
Revascularization Device  
3MM

Riptide™  
Aspiration System

React™  
Catheter

CAUTION: Federal (USA) law restricts this device to sale by or on the order of a physician. Indications, contra-indications, warnings and instructions for use can be found on the product labeling supplied with each device or can be viewed at <https://www.medtronic.com/manuals>. © 2021 Medtronic. All rights reserved. Medtronic, Medtronic logo and Engineering the extraordinary are trademarks of Medtronic. All other brands are trademarks of a Medtronic company. 9775 Toledo Way, Irvine, CA 92688 UC202207266 EN



Introducing:

# VECTOR

Experience the Magnitude of Motion



The VECTOR® Suspension System by Tollos transfers lead apron weight away from the body.

Work in comfort, with less stress and fatigue — and with no extra equipment necessary.

VECTOR allows unrestricted movement - with a full 7 ft radius.

VECTOR works with any lead apron and adjusts to any desired height or weight.

[Click here to watch VECTOR in motion.](#)

tollos  
Lightening the Load of Care



## Surpass Evolve® Flow Diverter

### 64-wire flow diversion

# Strong. Soft. Refined.

More wires mean better flow diversion. That's why Surpass Evolve Flow Diverter has 64 thinner wires, versus 48. 64 wire flow diversion is designed to give you: higher radial pressure for precise distal landing, more flexibility for excellent vessel wall apposition and higher mesh density for superior flow diversion.\* Visit [www.64wires.com](http://www.64wires.com) and see what makes Surpass Evolve Flow Diverter strong, soft and refined.



\*Testing performed by Stryker. Data on file at Stryker.

#### Surpass Evolve Flow Diverter System

##### RX ONLY

See package insert for complete indications, contraindications, warnings and instructions for use.

##### Intended use / indications for use

The Surpass Evolve Flow Diverter System is indicated for use in the endovascular treatment of patients (18 years of age and older) with unruptured large or giant saccular wide-neck (neck width  $\geq 4$  mm or dome-to-neck ratio  $< 2$ ) or fusiform intracranial aneurysms in the internal carotid artery from the petrous segment to the terminus arising from a parent vessel with a diameter  $\geq 2.5$  mm and  $\leq 5.0$  mm.

##### Contraindications

The Surpass Evolve Flow Diverter is contraindicated in the following patient types:

- Patients in whom the parent vessel size does not fall within the indicated range.
- Patients in whom antiplatelet and / or anticoagulation therapy (e.g., aspirin and clopidogrel) is contraindicated.
- Patients who have not received dual antiplatelet agents prior to the procedure.
- Patients with an active bacterial infection.
- Patients in whom the angiography demonstrates the anatomy is not appropriate for endovascular treatment due to conditions such as:
- Severe intracranial vessel tortuosity or stenosis; and/or
- Intracranial vasospasm not responsive to medical therapy.

##### Potential adverse events

Risks that may be associated with the use of the Surpass Evolve Flow Diverter System in the intracranial arteries include:

- Adverse reaction to anesthesia, contrast or antiplatelet/ anticoagulation agents
- Allergic reaction
- Aphasia
- Cardiac arrhythmia
- Cranial neuropathy
- Confusion, coma, change in mental status
- Death
- Device migration, fracture, misplacement
- Dissection of the parent artery
- Embolism (air, clots, device fragments)
- Groin injury (bleeding, pain, vessel/nerve damage)
- Headache
- Hemiplegia
- Hydrocephalus

- Implant or parent vessel stenosis
- Implant thrombosis/occlusion
- Infection
- Intracerebral bleeding
- Mass effect
- Myocardial infarction
- Neurological deficits
- Perforation or rupture of aneurysm
- Perforation of Parent Artery
- Progressive neurologic symptoms related to intracranial aneurysm (IA)
- Pseudoaneurysm formation
- Reaction to radiation exposure (i.e., alopecia, burns ranging in severity from skin reddening to ulcers, cataracts, delayed neoplasia)
- Renal failure
- Retroperitoneal hematoma
- Seizure
- Stroke
- Subarachnoid hemorrhage
- Thrombosis of parent artery or branch vessel
- Transient ischemic attack (TIA)
- Vasospasm

Risks that are eye related with the use of the Surpass Evolve Flow Diverter System may include:

- Amaurosis fugax/transient blindness
- Blindness
- Diplopia
- Reduced visual acuity/field
- Retinal artery occlusion
- Retinal ischemia
- Retinal infarction
- Vision impairment

##### Warnings

- Contents supplied STERILE using an ethylene oxide (EO) process. Do not use if sterile barrier is damaged. If damage is found, call your Stryker Neurovascular representative.
- For single patient use only. Do not reuse, reprocess or resterilize. Reuse, reprocessing or resterilization may compromise the structural integrity of the device and/or lead to device failure which, in turn, may result in patient injury, illness or death.

Reuse, reprocessing or resterilization may also create a risk of contamination of the device and/ or cause patient infection or cross-infection, including, but not limited to, the transmission of infectious disease(s) from one patient to another. Contamination of the device may lead to injury, illness or death of the patient.

- After use, dispose of product and packaging in accordance with hospital administrative and/ or local government policy.
- This device should only be used with adequate fluoroscopic guidance by physicians who have received appropriate training in interventional neuroradiology or interventional radiology, and training on the use of this device as established by Stryker Neurovascular.
- Persons allergic to nickel, cobalt chromium or platinum tungsten metal may suffer an allergic response to this system.
- Appropriate anti-platelet and anti-coagulation therapy should be employed in accordance with standard medical practice.
- **[Clinical Warning]** The safety and effectiveness of the device has not been evaluated or demonstrated for ruptured intracranial aneurysms.
- **[Clinical Warning]** A decrease in effectiveness has been observed in subjects aged  $> 65$  years old, subjects with history of smoking and history of prior non-target intracranial aneurysm treated.
- **[Clinical Warning]** Placement of multiple Surpass Evolve Flow Diversers may increase the risk of ischemic complications. Implantation of more than one Surpass Evolve Flow Diverter in non-clinical in vivo studies showed an increase in the generation of platinum microparticulates in the surrounding vessel tissues. The presence of the platinum microparticulates did not produce any adverse pathological changes such as overt inflammation or altered healing in the implanted vessels in the animals; however, the risk of platinum microparticulates in human patients is unknown.
- **[Clinical Warning]** Delayed aneurysm rupture may occur with large and giant intracranial aneurysms.

##### Cautions / precautions

- Carefully weigh the benefits of treatment vs. the risks associated with treatment using the device for each individual patient based on their medical health status and risks factors for intracranial aneurysm rupture during their expected life time such as age, medical comorbidities, history of smoking, intracranial aneurysm size, location, and morphology, family history, history of prior asymptomatic subarachnoid hemorrhage (aSAH), documented growth of intracranial aneurysm on serial imaging, presence of multiple intracranial aneurysms, and presence of concurrent pathology. The benefits of device use may not outweigh the risks associated with the device in certain patients; therefore, judicious patient selection is recommended.

• This device has not been evaluated for pediatric use.

- The safety and effectiveness of the device has not been established in the treatment of small and medium wide-neck intracranial aneurysms.
- Experience with endovascular implants indicates that there is a risk of stenosis. Subsequent stenosis may require dilatation of the vessel segment containing the device. The risks and long-term outcome following dilatation of endothelialized devices is unknown at present.
- A thrombosing aneurysm may aggravate pre-existing or cause new symptoms of mass effect and may require medical therapy.
- Operators should take all necessary precautions to limit X-radiation dose to patients and themselves by using sufficient shielding, reducing fluoroscopy times, and modifying X-ray technical factors where possible.
- Lower intracranial aneurysm occlusion rates may be associated with giant intracranial aneurysms ( $> 25$ mm).
- Lower intracranial aneurysm occlusion rates may be associated with implants that are not fully apposed to the vessel wall.

##### MRI safety information

Non-clinical testing demonstrated that the Surpass Evolve Flow Diverter is MR Conditional for single and overlapping up to 60mm in length. A patient with the Surpass Evolve Flow Diverter can be scanned safely in an MR system under the following conditions:

- Static magnetic field of 1.5 Tesla and 3 Tesla, only
- Maximum spatial gradient magnetic field of 3,000 Gauss/cm (30 T/m)
- Maximum MR system reported, whole body averaged specific absorption rate (SAR) of 2 W/kg in the Normal Operating Mode

Under the scan conditions defined, the Surpass Evolve Flow Diverter is expected to produce a maximum temperature rise of 3.0°C after 15 minutes of continuous scanning (i.e., per pulse sequence). In non-clinical testing, the image artifact caused by the Surpass Evolve Flow Diverter extends approximately 10mm from this implant when imaged using a gradient echo pulse sequence and a 3 Tesla MR system. The lumen cannot be visualized on gradient echo or T1-weighted, spin echo pulse sequences.

Caution: The Surpass Evolve Flow Diverter may create local field inhomogeneity and susceptibility artifacts during magnetic resonance angiography (MRA), which may degrade the diagnostic quality to assess effective intracranial aneurysm treatment.

The health state of the patient or the presence of other implants may require reduction of the MRI limits.

Stryker or its affiliated entities own, use, or have applied for the following trademarks or service marks: Stryker, Surpass Evolve. All other trademarks are trademarks of their respective owners or holders.

The absence of a product, feature, or service name, or logo from this list does not constitute a waiver of Stryker's trademark or other intellectual property rights concerning that name or logo.

Copyright © 2021 Stryker  
AP003610 v1.0



Stryker Neurovascular  
47900 Bayside Parkway  
Fremont, CA 94538  
[www.stryker.com](http://www.stryker.com)  
Date of release: OCT/2021  
EX\_EN\_US



# Take your technique to the **next level** with the **TriVecta™** Thrombectomy Platform


Aspiration, combination or both – next generation devices for your technique

AXS Infinity LS Plus Long Sheath

AXS Vecta 74 Intermediate Catheter

Trevo NXT  
ProVue Retriever

LEARN MORE



## TriVecta Thrombectomy Platform

### RX ONLY

See package insert for complete indications, contraindications, warnings and instructions for use.

### Indications for use

AXS Infinity LS Plus Long Sheath: The AXS Infinity LS Plus Long Sheath is indicated for the introduction of interventional devices into the peripheral, coronary, and neuro vasculature. AXS Vecta Intermediate Catheter:

(1) The AXS Vecta Aspiration Catheter, as part of the AXS Vecta Aspiration System is indicated in the revascularization of patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease (within the internal carotid, middle cerebral – M1 and M2 segments, basilar, and vertebral arteries) within 8 hours of symptom onset. Patients who are ineligible for intravenous tissue plasminogen activator (IV t-PA) or who failed IV t-PA therapy are candidates for treatment. (2) The AXS Vecta Intermediate Catheter is indicated

for use in facilitating the insertion and guidance of appropriately sized interventional devices into a selected blood vessel in the peripheral and neurovascular systems. The AXS Vecta Intermediate Catheter is also indicated for use as a conduit for retrieval devices. Trevo NXT ProVue Retriever: (1) The Trevo Retriever is indicated for use to restore blood flow in the neurovasculature by removing thrombus for the treatment of acute ischemic stroke to reduce disability in patients with a persistent, proximal anterior circulation, large vessel occlusion, and smaller core infarcts who have first received intravenous tissue plasminogen activator (IV t-PA). Endovascular therapy with the device should start within 6 hours of symptom onset. (2) The Trevo Retriever is intended to restore blood flow in the neurovasculature by removing thrombus in patients experiencing ischemic stroke within 8 hours of symptom onset. Patients who are ineligible for intravenous tissue plasminogen activator (IV t-PA) or who fail IV t-PA therapy are candidates for treatment. (3) The Trevo Retriever is indicated for use to restore blood flow in the neurovasculature by removing thrombus for the treatment of acute ischemic stroke to reduce disability in patients with a persistent, proximal


anterior circulation, large vessel occlusion of the internal carotid artery (ICA) or middle cerebral artery (MCA)-M1 segments with smaller core infarcts (0-50cc for age < 80 years, 0-20cc for age ≥ 80 years). Endovascular therapy with the device should start within 6-24 hours of time last seen well in patients who are ineligible for intravenous tissue plasminogen activator (IV t-PA) or who fail IV t-PA therapy.

**For Important Safety Information, please visit [info.stryker.com/TriVecta](http://info.stryker.com/TriVecta) or through the QR code.**


Stryker or its affiliated entities own, use, or have applied for the following trademarks or service marks: AXS Infinity LS, AXS Vecta, Stryker, Trevo NXT. All other trademarks are trademarks of their respective owners or holders.

The absence of a product, feature, or service name, or logo from this list does not constitute a waiver of Stryker's trademark or other intellectual property rights concerning that name or logo.





**UNCONSTRAINED DESIGN**  
**UNMATCHED ACCESS**  
**PREDICTABLE CONTROL**



**SCIENTIA**



SVIN2022

LOS ANGELES

2022 SVIN ANNUAL MEETING

NOVEMBER 16–19, 2022  
WESTIN BONAVENTURE HOTEL & SUITES  
LOS ANGELES, CA

